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1. Introduction  
 
1.1 The vacuolar (H+)-ATPase (V-ATPase) 
 
The vacuolar (H+) ATPase (v-ATPase) is a large multimeric complex that couples 
ATP hydrolysis to transport of protons. V-ATPase is composed of 14 subunits 
organized in two domains : a peripheral V1 domain that hydrolyses ATP and an 
integral V0 domain that translocates protons by a rotary mechanism (Nishi and 
Forgac, 2002) (Figure 1). V-ATPase is responsible for membrane trafficking 
processes such as receptor-mediated endocytosis, intracellular trafficking of 
lysosomal enzymes, and acidification of intracellular organelles in all eukaryotic cells 




As mentioned before, V1 domain is responsible for ATP hydrolysis. It is composed by 
eight subunits (A-H) some of which present in more than one copy. V1 domain 
includes three copies of subunits A and B, two copies of subunits G and E, one or 
more copies of subunit H and a single copy of the other subunits (C, D, F) (Figure 1). 
The three subunits A and the three subunits B form a hexamer of about 400KDa: 
They alternate in the hexame, to form a cylinder, in which three ATP-hydrolysis sites 
are present between A and B subunits. Most of the residues, which participates in the 
catalytic site, belong to subunit A. In the other interfaces, a binding site for 
nucleotides is present, and most of the residues which participate in this site belong to 
subunit B, which seems to have a modulatory role (Nishi and Forgac, 2002). Subunits 
D and F serve as a rotor that couples the energy derived from ATP hydrolysis to the 
rotation of subunits in the V0 domain (Forgac, 2007). Subunits G and E (Ohira et al., 
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2006) form two heterodimers (Féthière et al., 2005) which probably interact with 
subunit C and subunit H respectively (Wilkens et al., 2004) (Zhanga et al., 2006) . 
Together, they act as a stator, preventing the rotation during ATP hydrolysis. 
The integral V0 domain serves as a proton translocator across the membrane. It is 
composed of subunits a, d, e, c and c’’. There are four or five copies of subunit c and 
single copies of the remaining subunits (Nishi and Forgac, 2002). Subunits c, c’ and 
c’’ are highly hydrophobic, they are arranged to form a proteolipid ring (Wilkens et 
al., 2004). Each of them contains a buried glutamate (Glu) residue located in 
transmembrane helix-4 (TM4) of subunit c and c’ and TM3 of subunit c’’. These Glu 
residues undergo protonation during proton transport (Nishi and Forgac, 2002). The 
a-subunit has a hydrophilic N-terminal domain that is oriented towards the 
cytoplasmic surface, and a C-terminal domain that contains eight or nine 
transmembrane helices (Nishi and Forgac, 2002). In TM7 there is a buried arginine 
(Arg) residue also required for proton transport (Nishi et al., 2001). 
The V0 domain also contains subunit d, which provides connection between the V1 






Figure1. Structure of v-ATPase. 
The vacuolar (V‑)ATPase complex is composed of a peripheral domain (V1, shown in yellow 
and orange), which is responsible for ATP hydrolysis, and an integral domain (V0, shown in 
blue and grey), which is involved in proton translocation across the membrane. The core of 
the V1 domain is composed of a hexameric arrangement of alternating A and B subunits, 
which participate in ATP binding and hydrolysis. The V0 domain includes a ring of 
proteolipid subunits (c, c′ and c′′) that are adjacent to subunits a and e. The V1 and V0 
domains are connected by a central stalk, composed of subunits D and F of V1 and subunit d 
of V0, and multiple peripheral stalks, composed of subunits C, E, G, H and the N‑terminal 
domain of subunit a . Subunit a possesses two hemi-channels and a crucial buried Arg 





V-ATPases are large multi-subunit complexes that operate in multiples intracellular 
organelles and at plasma membrane. Each component is expressed in the right 
quantity, correctly assembled in the final enzyme and targeted to the ultimate 
destination. This is particularly challenging since v-ATPase is made by peripheral and 
integral components. Indeed, both transcriptional and post-transcriptional 
mechanisms regulate these processes (Holliday et al., 2014). 
In yeast, the assembly of V0 domain is dependent on a set of dedicated chaperones 
that reside in the endoplasmic reticulum (ER) (Laurie et al., 2004), such as the 
integral proteins Vma12 (vacuolar membrane ATPase activity-12), Vma21, the 
peripheral membrane protein Vma22 and the identified Pkr1 (Graham et al., 1998, 
Davis-Kaplan et al., 2006). Vma21 appears to promote the assembly of the 
proteolipid ring in the ER and the binding of subunit d to this complex, through the 
interaction with subunit c’. It also accompanies V0 exit from ER. Vma12 and Vma22 
interact transiently with a-subunit and mediate its assembly with the proteolipid ring 
(Graham et al., 2003). Pkr1 increases the efficiency of V0 assembly and export 
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(Davis-Kaplan et al., 2006). Homologous of these chaperones have been identified in 
higher eukaryotes (Per Malkus et al., 2004), but their role in v-ATPase assembly 
remains to be established (Forgac, 2007) 
The translation of V1 domain subunits happens in the cytoplasm, their assembly can 
occur in absence of subunit C, provided that all the remaining subunits are present 
(Kane et al., 2006). There is an alternative route for the assembly of the two domains: 
subunit A begins to assemble with V0 subunits (in particular, the a-subunit) before V0 
is completely assembled (Kane et al., 2006). The conditions that might promote one 
pathway over the other are still unclear. Once the V0 domain is complete, it is 
exported to the Golgi apparatus. Here, Vma21 can be recycled back to the ER, and 
the V0 domain can interact with V1 domain on the cytoplasmic side: assembly of V0 
complexes can occur either with almost fully assembled V1 domain (lacking subunit 




1.4 Proton transport 
 
The v-ATPase rotary mechanism has been studied in bacteria (Imamura et al., 2003) 
and yeast (Hirata et al., 2003). Protons are first loaded into the V0 domain (Figure 2a): 
the cytoplasmic side of a-subunit has an aqueous hemi-channel trough which protons 
can reach the buried Glu residues in the proteolipid subunits (E137 in subunit c, E145 
in subunit c’ and E108 in subunit c’’) and protonate them as previously proposed for 
ATP synthase (Steven et al., 2000) (Fillingame et al., 2003) (Figure. 2b). The residues 
remain protonated as they are subsequently placed in contact with the hydrophobic 
environment of the bilayer. 
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Rotation is facilitated by ATP hydrolysis at catalytic sites located on the interface of 
subunits A and B in the V1 domain. This hydrolysis drives the rotation of the central 
rotor (subunit D and F) of V1 connected to subunits d and the ring of proteolipid 
subunits of V0 (Figure 2c). 
Following rotation, protonated Glu residues reach another aqueous hemi-channel on 
luminal side of subunit a, from which they enter into the lumen (Figure 2d). For 
proton transport a crucial buried Arg residue (R735) in transmembrane helix-7 (TM7) 
of subunit a is absolutely required. Other buried residues of the c-terminal subunit a 
(H743, E789, R799) line the lumenal hemi-channel trough which protons exit the 
membrane, thereby making the lumen more acidic (Nishi and Forgac, 2002). 
 
 
Figure 2: Proton transport cycle. 
Protons enter through the a subunit from a hemi-channel on the cytoplasm side (a), and 
interact with buried Glu residues in the proteolipid subunits ( E137 in subunit c, E145 in 
subunit c’ and E108 in subunit c’’) protonating them (b). The hydrolysis of ATP on the 
ctoplasmic side facilitates the rotation of the rotary assembly (subunits D, F, d and the ring 
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of proteolipid subunit c, c’ and c’’) which causes active transport of protons (c). Protonated 
Glu residues reach another aqueous hemi-channel on luminal side of subunit a, from which 
they can enter the lumen. To enter the lumen, it is important the interaction between protons 
and the Arg735 residue (d). From Forgac, 2007. 
 
1.5 Functions of v-ATPase 
 
The canonical functions of v-ATPase rely on its ability of pumping H
+
 and its 
function is crucial for the characteristic Ph of each intracellular organelles. V-
ATPases-dependent acidification drives various processes as receptor-ligand 
uncoupling after endocytosis and to activate enzymes such as cathepsins. Additional 
roles of V-ATPase are the creation of an electrochemical gradient in the secretory 
vesicles to couple the neurotransmitters transport inside the vesicle and a more recent 









Figure 3: functions and localizations of v-ATPases. 
V-ATPase is located on intracellular organelles like sorting endosome, multivesicular body, 
lysosome, late endosome, secretory vesicle. V-ATPase can acidify intracellular organelles 
and this process is necessary for their function. From Forgac, 2007  
 
1.6 Membrane Traffic 
 
Extracellular ligands can be internalized by receptor-mediated endocytosis from the 
plasma membrane and trafficked to the sorting endosome (Maxfield et al., 2004). 
Here v-ATPases generate acidic pH, which drives the uncoupling of internalized 
ligand-receptor complexes (Forgac, 2007). This facilitates the recycling of 
unoccupied receptors to the plasma membrane and targeting of ligands to the 
lysosome for degradation through multivesicular bodies (MBVs, also known as 
“endosomal carrier vesicles”) (Maxfield et al., 2004). Formation of MVBs is also 
dependent on lumenal acidic pH (Clague et al., 1994). 
Acidification of late endosomes by the v-ATPase is also important in intracellular 
trafficking of newly synthetized lysosomal enzymes from the Golgi to lysosomes. 
These enzymes have a Mannose-6-phosphate tag recognized by their receptor in the 
Trans-Golgi network (TGN) which allows the delivery of the complex to the late 
endosomes (Ghosh et al., 2003). Here, low pH provided by v-ATPases causes the 
release of the inactive enzyme and the recycling of the receptor to the TGN. 
Progression to the acidic lysosome results in a conformational change of the enzyme 
and thus its activation. The low pH also triggers conformational changes in proteins, 
making them more susceptible to proteolytic degradation. Within these 
compartments, v-ATPases provide the necessary proton gradient to drive coupled 
transport of small molecules and ions. Therefore, breakdown products of 





/amino acid cotransporters using the proton gradient generated by v-
ATPases (Hinton et al., 2009).  
Moreover, the proton and membrane potential gradients established by the v-ATPases 
are used to drive the uptake of small molecules, such as neurotransmitters, as it will 
be discussed in follow section (1.8.1). 
Furthermore, since v-ATPase interacts with actin (Vitavska et al., 2003), it has been 
speculated that the v-ATPase promotes the regulation of cytoplasmic G-actin pool, as 
well as crosslinking and stabilization of actin into filaments (Vitavska et al., 2005). 
By connecting vesicles to actin filaments, the v-ATPase is thought to play a role in 
vesicular sorting and transport during exocytosis and recycling (Maxson et al., 2014). 
 
1.7 Membrane fusion 
 
One novel function of v-ATPase is membrane fusion. There are evidences of the 
transmembrane electrochemical H
+
 gradient requirement for fusion of synaptic or 
secretory vesicles (Poëa-Guyon et al., 2013). However, subsequent studies have 
pointed out a structural role of the v-ATPase, largely based on yeast vacuolar fusion 
experiments (Peters et al., 2001). It was proposed that, following soluble NSF 
attachment protein receptor (SNARE)-mediated docking, the V0 domains of two 
adjacent membranes form a trans-complex, thereby creating a fusion pore that aids 
vesicle fusion through a mixing of the highly hydrophobic proteolipid subunits of the 
two V0 domains. Subsequent experiments in synaptic vesicle release in Drosophila 
neurons (Hiesinger et al., 2005) and fusion cuticle-containing vesicles of epidermal 
cells (Liegeois et al., 2006) in C. elegans suggest that this mechanism is not only 
restricted to the yeast’s vacuole. However, the debate is still ongoing, with some 
groups supporting the original conclusion, namely the acidification, rather than the 




1.8 V-ATPase in neurons 
 
Despite the ubiquitous role in pH homeostasis and intracellular signaling pathways, 
the v-ATPase complex is expressed at high levels in neurons where it plays additional 
and unique roles in neurotransmitter loading into synaptic vesicles and in the 
regulation of synaptic transmission (Morel and Poëa-Guyon, 2015; Bodzeta et al., 
2017). 
One of the major roles of v-ATPases in neurons is to provide the electrochemical 
potential, acidic and positive inside the synaptic vesicle (SV), that contributes to the 
loading of the SVs with neurotransmitters by specific vesicular transporters (Edwards 
et al., 2007). Debated findings have suggested that v-ATPase membrane domain (V0) 
also contributes to Ca2
+
-dependent transmitter release via a direct role in vesicle 
membrane fusion (Morel and Poëa-Guyon, 2015). 
 
1.8.1 Energy coupling 
 
In neurons, neurotransmitters (NTs) are synthesized, stored and released in highly 
specialized domains, the nerve terminals, where they are accumulated in synaptic 
vesicles by specific transporters (Edwards et al., 2012). 
V-ATPases are present in the membrane of every synaptic vesicle in one or two 
copies (Stadler and Tsukita 1984; Yamagata et al., 1989) and they generate a large 
electrochemical proton gradient with pH around 5.5 inside the synaptic vesicles 
(Michaelson et al., 1980; Füldner et al., 1982). Acidification of synaptic vesicles by 
v-ATPase energizes the accumulation of neurotransmitters in these organelles and is 
therefore required for efficient synaptic transmission. 
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The filling of synaptic vesicles with neurotransmitter depends on the energy stored in 
a H
+
 electrochemical gradient (ΔμH
+
) produced by the v-ATPase. ΔμH
+
 in turn 
comprises both a chemical gradient (ΔμH) and membrane electrical gradient (Δψ), 
and the transport of all classical transmitters into synaptic vesicles depends on these 
gradients.  
Pharmacological inhibition of v-ATPase activity blocks neurotransmitter loading 
without affecting neurotransmitter release from already loaded vesicles (Poëa-Guyon 
et al., 2013) as seen blocking neurotransmitter transporters. 
From pharmacological and biochemical data, it has been estimated that only one or 
two molecules are present per synaptic vesicle (Takamori et al., 2006), laying 
emphasis on the strategic position of this large protein complex in the functional 
control of loading and, possibly, of exocytosis of SVs. 
 
1.8.2 Synaptic vesicle fusion 
 
Neurotransmitter release by synaptic vesicle exocytosis proceeds in several steps: 
The neurotransmitter is internalized, accumulated and stored in synaptic vesicles 
(SVs), by specific transporters that use the large electrochemical proton gradient 
generated by v-ATPase as described above (Edwards et al., 2012). It is generally 
assumed that all the vesicles in the nerve terminals are filled with NT, but it could 
also not to be the case, especially under sustained synaptic activity. SVs acquire 
competence for release, entering in the releasable pool, through the docking and 
priming steps (Imig et al., 2014). As in intracellular membrane fusion events, this 
involves SNARE proteins that associate in a tight SNARE complex: VAMP2 (also 
named synaptobrevin-2), the v-SNARE protein anchored at synaptic vesicle 
membrane, forms a trans-complex with two SNARE proteins of the presynaptic 
membrane (t-SNAREs): syntaxin-1 and SNAP-25. The soluble protein Munc-18 
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binds sintaxin-1 in its closed conformation, and remains attached during the complex 
formation, controlling the proper SNARE complex assembly (Südhof et al., 2009). In 
addition, SNARE complex assembly is also controlled by Munc-13, which binds 
proteins in the active zone (the specialized portion of the presynaptic plasma 
membrane where synaptic fusion takes place), helping in positioning the synaptic 
vesicle in close proximity to voltage-gated calcium channels (Südhof et al., 2012). 
The calcium-influx, generated by the arrival of the Action Potentials (APs), triggers 
neurotransmitter release from primed vesicles via the action on additional proteins as 
synaptotagmins and complexins. Synaptotagmins are calcium-binding synaptic 
vesicle proteins that associate with SNARE complex and clamp it until the calcium-
binding. Complexins are small soluble proteins that binds to the assembled SNARE 
complexes and act as synaptotagmin cofactors (Südhof et al., 2009). Upon calcium 
entry, synaptotagmins trigger membrane fusion. The two lipid bilayers merge at the 
contact site, and then an aqueous pore (the fusion pore) opens, connecting the 
synaptic vesicle lumen with the extracellular space, allowing neurotransmitters to be 
released. Expansion of the fusion pore makes the synaptic vesicle completely fuse. 
Alternately, the fusion pore may close without expanding, a process called kiss-and-
run. The nature of the fusion pore, purely lipidic or containing proteolipids or 
proteins, is still unknown. 
In recent times, some works support the hypothesis the hydrophobic V0 v-ATPase 
membrane domain could be involved in membrane fusion (Peters et al., 2001) and 
neurotransmitter release (Morel et al., 2011). 
As noted above, at nerve terminals v-ATPase is present both on synaptic vesicle 
membrane and on the pre-synaptic membrane. The functional significance of its 
expression at pre-synaptic plasma membrane is a matter of debate, even if it has been 
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recently shown to be involved in stimulation-dependent alkalinization of the 
cytoplasm, which may regulate endocytosis (Zhang et al., 2010). 
The V0 membrane domain of the v-ATPase was shown to interact with proteins that 
are involved in exocytosis: the SNAREs and calmodulin in its calcium-bound form 
and this would regulate the SNARE complex assembly (Wang et al., 2014). 
VAMP-2 associates with V0 via its membrane-proximal region, and this interaction 
excludes subunits of the V1 catalytic sector. A VAMP-2 binding site has been 
demonstrated in c-subunit, in the loop between the transmembrane domains 3 and 4, 
which is exposed to the cytosol after dissociation of V1. This interaction does not 
affect the formation of the SNARE complex, it occurs probably as a cis complex 
within the same membrane. The stoichiometry estimated is 1:1 thus the c-subunit 
hexamer could potentially bind six v-SNARE (Di Giovanni et al., 2010). 
An interaction of V0 with the t-SNARE syntaxin-1 has also been reported (Hiesinger 
et al., 2005; Wang et al., 2014), in agreement with data from yeast (Peters et al., 
2001). Syntaxin-1 appears to bind to coiled-coils domains at the N-terminus of the a1 
Drosophila orthologue (Hiesinger et al., 2005). 
This interaction could occur either as a trans complex formed by a vesicular V0 and 
syntaxin-1 in the presynaptic membrane, therefore, concerning a limited number of 
already docked synaptic vesicles, or as a cis-complex within the presynaptic plasma 
membrane, unrelated to secretory vesicles. The functional relevance of the latter 
remains to be elucidated. 
V0 was also shown to interact with Ca2+/calmodulin (Peters et al., 2001; Wang et al., 
2014) via a calmodulin-binding site in the a-subunit. Calmodulin is a small, 
ubiquitous Ca2+-dependent regulator of cell biological processes. During prolonged 
stimulations, calmodulin bound to Munc-13 proteins promoting synaptic vesicle 
priming and replenishment of the readily releasable pool of vesicles. Priming might 
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also include calmodulin binding to SNAREs (Di Giovanni et al., 2010). Like 
complexins, calmodulin bound to VAMP-2 seems to act as a clamp that can be 
removed by synaptotagmin (Di Giovanni et al., 2010). By interacting with 
calmodulin, subunit a1 can regulate the formation of SNARE complexes (Wang et al., 
2014). Instead Bodzeta et al. provide direct evidence, that unlike reported previously, 
v-ATPase does not play a direct role in SV fusion. Instead, v-ATPase modulates 
release upstream of docking to facilitate fusion of fully acidified and hence, 
neurotrasmitter-loaded SVs. Their results demonstrate that : (1) under resting 
conditions, the cytosolic V1 domain binds with low affinity to the V0 membrane 
sector of SVs at presynaptic boutons; (2) the binding equilibrium between assembled 
and disassembled state of the v-ATPase is shifted toward the assembled state on non-
acidified SVs, (3) SV fusion competence is decreased upon locking v-ATPase in an 
assembled state; and (4) SVs with attached V1 in principle undergo robust release 
when enough time is granted for docking and priming (Bodzeta et al., 2017).  
 
1.8.3 V0-ATPase as a sensor of luminal pH 
 
Based on the studies on secretory granules and their exocytosis in PC12 cells (Poëa-
Guyon et al., 2013), it has also been proposed a role for the V0 domain as a sensor of 
the luminal pH. Dissipating the intra-granular pH gradient was associated with an 
inhibition of exocytosis, and this appears correlated with the V1-V0 association status 
in secretory granules. It probably concerns a priming step that confers the competence 
for release, before the formation of trans-SNARE complexes. At acidic pH, V1 would 
dissociate from V0, allowing it to interact with the exocytotic complex. V0 could also 
allow the exocytotic machinery to discriminate fully loaded an acidified vesicles from 
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vesicles undergoing neurotransmitter reloading (Poëa-Guyon et al., 2013; Morel and 
Poëa-Guyon, 2015). 
Summarizing, v-ATPases might control neurotransmitter storage and release: in a V1-
V0 conformation, v-ATPase translocates protons and energizes the accumulation of 
neurotransmitter within synaptic vesicles (Edwards et al., 2007). 
When synaptic vesicles are filled with neurotransmitter, the proton electrochemical 
gradient is no longer dissipated and V0 could behave as an intravesicular pH 
sensor.V0 changes its conformation and V1 is released. V0 is now competent to 
participate in the regulation of SNARE complex assembly. A single c-subunit 
hexamer present in the vesicle could function as scaffolding to organize higher order 
SNARE assemblies optimal for fusion. The v-SNARE VAMP2 interacts with the 
proteolipid c-subunits and the t-SNARE syntaxin-1 with the N-terminal cytosolic 
domain of the a-subunit. These interactions, which might be regulated by calmodulin 
and calcium, occur during the priming-docking step allowing synaptic vesicles to 
enter the readily releasable pool. 
Finally, V0 might facilitate lipid mixing and the formation of the fusion pore during 
the fusion step: the hexameric V0 c-subunit is potentially a pore-forming structure, 
although it does not function as such during proton transport. However, another 
possibility is that upon interaction between t-SNARE and v-SNARE, the energy of 
this zipping is enough to pull apart V0 subunits, and lipids could infiltrate with full 






Figure 4: possible roles of V0 subunit in synapse: 
A, in association with V1, V0 translocates protons inside the synaptic vesicle to energize 
neurotransmitter influx. B, when synaptic vesicle is filled with neurotransmitters, V0 acts as 
pH sensor, changing conformation and causing the release of V1. C, V0 could participate in 
the regulation of SNARE complex assembly. D, finally, upon calcium influx, V0 could 
facilitate lipid mixing and the formation of the fusion pore. Modified from Morel et al. 2015  
 
 
1.8.4 V-ATPase and diseases 
 
In humans, a redundant set of subunits is encoded by 22 autosomal genes, allowing 
the composition of diverse v-ATPase complexes with specific properties and tissue 
expression. Among these, only six have been associated to several recessive 
disorders, including distal renal tubular acidosis and hearing loss (ATP6V1B1 and 
ATP6V0A4) (Karet et al., 1999; Stover et al., 2002), osteopetrosis, with 
macrocephaly, progressive deafness, blindness, hepatosplenomegaly, and severe 
anemia (ATP6V0A3) (Kornak et al., 2000; Frattini et al., 2000), cutis laxa, a systemic 
disorder with severe neurological impairment featuring structural brain abnormalities, 
severe delay, and seizures (ATP6V0A2, ATP6V1E1 and ATP6V1A) (Fischer et al., 
2012; Van Damme et al., 2017) (Table1). Two allelic dominant disorders, 
Zimmermann-Laband syndrome type 2, featuring facial dysmorphisms and 
intellectual disability (Kortum et al., 2015) and a form of congenital deafness with 




Table1. V-ATPase subunits associated with human disorders 
 
1.9 Early onset Epileptic encephalopathies 
 
Developmental brain disorders (DBDs) are a group of severe conditions characterized 
by developmental brain dysfunctions and manifesting with different and often 
concomitant neuropsychiatric symptoms such as intellectual disability, behavioral 
abnormalities, motor defects and seizures. The physio-pathological landscape of 
neurodevelopmental disorders implicates a range of biological mechanisms including 
channelopathies, transcriptional dysregulations, impaired DNA repair/remodelling 
and metabolic defects. Early onset epileptic encephalopathies (EOEEs) are severe 
DBDs in which cognitive, sensory, and motor development is impaired by recurrent 
clinical seizures and/or major interictal paroxysmal activity during the neonatal or the 
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early infantile periods. They are characterized by rapid deterioration of brain function 
with progressive disturbance of cognitive, sensory or motor function (Nabbout et al., 
2003). EOEEs are genetically heterogeneous disorders: over 100 genes have been 
suggested to be involved in the etiology of these syndromes (Lemke et al.,2012). 
Many EOEE cases are sporadic, occurring in patients with no family history of 
seizures or epilepsies (Allen et al., 2013). Sporadic cases are commonly caused by 
autosomal dominant de novo mutations in genes encoding neuronal proteins. Next-
generation sequencing (NGS) has contributed to the identification of many 
monogenic epilepsy syndromes. Moreover, information emerging from NGS studies 
allows to better understand mechanisms of these pathologies, progressively 
delineating specific entities previously gathered under the generic definition of 
epileptic encephalopathies (Mei et al., 2017). In addition to many genes coding for 
ion channels , there is also a significant group of genes coding for synaptic proteins, 










       Table2. Genes coding for synaptic proteins associated with 
epileptic encephalopathies 




2. Aim of the study 
 
The aim of the study is to analyze the functional consequences of the novel 
pathogenic mutations in ATP6V1A described in patients with EOEE. As experimental 
models we employed transfected HEK293 cells and patients’ lymphoblasts to assess 
the effects of the mutations on the stability of ATP6V1A protein and on organelle 




Our collaborators at Meyer Children’s Hospital of Florence have identified, through 
whole exome sequencing, de novo heterozygous mutations in ATP6V1A, encoding the 
A subunit of v-ATPase, in four patients with developmental encephalopathies with 
epilepsy. The aim of my PhD project is to analyze the functional consequences of the 
novel pathogenic mutations described in EOEE in v-ATPase function, in neuronal 
development and synaptic mantainance. During my PhD i addressed the impact of 
p.Asp349Asn and p.Asp100Tyr mutations on ATP6V1A expression and function by 
analysing HEK293T cells overexpressing ATP6V1A and patients' lymphoblasts. The 
p.Asp100Tyr mutant was characterized by reduced expression level due to increased 
degradation. Conversely, no significant decrease in expression and clearance was 
observed for the p.Asp349Asn mutant. In HEK293T cells overexpressing either 
pathogenic or control variants, the p.Asp349Asn mutation significantly increased 
Lysotracker fluorescence with no effects on EEA1 and LAMP1 expression. 
Conversely, the p.Asp100Tyr mutation decreased both Lysotracker fluorescence and 
LAMP1 levels, leaving EEA1 expression unaffected. Both variants impaired v-
ATPase recrutiment to autophagosomes. Parallel experiments performed on patients’ 
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lymphoblasts using the ratiometric Lysosensor probe revealed a decrease in the pH of 
endocytic organelles for the p.Asp349Asn mutation and a reduced expression of 
LAMP1 with no effect on the pH for the p.Asp100Tyr mutation. The data 
demonstrate a gain of function for the p.Asp349Asn mutation characterized by an 
increased proton pumping in intracellular organelles, and a loss of function for the 
p.Asp100Tyr mutation with decreased expression of ATP6V1A and reduced levels of 
lysosomal markers.  
I also expressed p.Asp349Asn and p.Asp100Tyr in rat hippocampal neurons and 
confirm significant and opposite effects in lysosomal labeling. However, both 
mutants caused a similar defect in neurite elongation accompanied by a loss of 
excitatory inputs, revealing that altered lysosomal homeostasis markedly affects 
neurite development and synaptic connectivity, uncovering a novel role for v-ATPase 
in neuronal development.  
This study provides evidence that de novo heterozygous ATP6V1A mutations cause a 
developmental encephalopathy with a pathomechanism that involves perturbations of 
lysosomal homeostasis and neuronal connectivity. 
4 Materials and methods  
 
ATP6V1A constructs  
 
We synthesized wild-type (w.t.) and mutant (p.Asp100Tyr and p.Asp349Asn) human 
ATP6V1A cDNAs in vitro and cloned in pLVX-IRES-mCherry vector by Biomatik 
(Cambridge, Canada). We performed Sanger sequencing of all constructs to check the 
correct inserts orientation and validate their sequence. For silencing ATP6V1A we 






Cell culture and transfection 
 
Human Embryonic Kidney-derived 293T (HEK) cells were maintained at 37°C in a 
humidified 5% CO2 incubator in in DMEM (Life Technologies) supplemented with 
10% FBS, 2 mM L-glutamine and 1% Penicillin-Streptomycin. Cells were transfected 
with Lipofectamine 2000 (Life Technologies) according to the manufacturer’s 
instructions. HEK cells were starved by medium withdrawal for 2 hrs. Lymphoblatsts 
were prepared by infecting lymphocytes obtained from patients and their parents with 
the Epstein-Barr virus (EBV) in vitro using standard protocols and maintained in 
RPMI 20% FBS, 1 mM L-glutamine and 10 mM D-glucose. Primary cortical neurons 
were prepared from E18 brains of Sprague Dawley (SD) rats as previously described 
(Verstegen et al. 2014). Neurons were transfected using Lipofectamine 2000 at 7 or 




Protein lysates from HEK, lymphoblast and neuronal cultures were extracted in lysis 
buffer (50 mM Tris [pH 7.5], 150 mM NaCl, 0.1% SDS, 1% Nonidet P40, 0.2 mM 
phenylmethylsulfonyl fluoride, 2 μg/ml pepstatin, and 1 μg/ml leupeptin 
) and then separated by SDS-PAGE and assayed by immunoblotting with the 
following primary antibodies: anti-ATP6V1A (1:1000; #ab137574, Abcam), anti-
ATP6V0D (1:1000; #ab155594, Abcam) anti-ATP6V1B2 (1:2000; #ab73404, 
Abcam), anti-LAMP1 (1:1000; #ab24170, Abcam), anti-EEA1 (1:5000; #610457, BD 
Bioscience, USA), LC3B (1:1000; #7543 Sigma-Aldrich), p62 (1:1000, #P0067 
Sigma-Aldrich), anti-GAPDH (1/1000; #SC-25778, Santa Cruz Biotechnology), anti-
VAMP2 (1:1000; #104202; Synaptic Systems, Gottingen, Germany); anti-V-GLUT1 
(1:1000; #135304; Synaptic Systems) anti-PSD95 (1:1000; #SC- 32290, Santa Cruz 
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Biotechnology). anti-vGAT (#131004; Synaptic Systems), anti NMDA R2B 
(#ab28373; Abcam) and anti-Gephyrin (#147 011; Synaptic Systems). Bafilomycin 
A1was from Tocris Bioscience (Cookson, USA) 
Degradation assay 
 
HEK cells were transfected with ATP6V1A wild type (w.t.), ATP6V1A Asp349Asn 
or ATP6V1A Asp100Tyr and treated with 10 µg/ml of cycloheximide (C4859, 
Sigma-Aldrich) 24 hrs after transfection. Cells were lysed at different times after 
cycloheximide addition and analysed by Western Blotting. Protein level is expressed 
with respect to ATP6V1A content in the cells collected at time zero and treated with 
vehicle (DMSO). 
 
Immunocytochemistry and fluorescence microscopy 
 
Transfected primary cortical neurons or HEK cells were fixed in 4% 
paraformaldehyde in PBS, permeabilized in 0.1% Triton X-100, blocked with 2% 
FBS /0.05% Tween-20 in PBS and incubated with the various antibodies in blocking 
solution. Samples were mounted in ProLong Gold antifade reagent with DAPI 
(#P36935, Thermo-Fisher Scientific). Capture of confocal images was performed 
using a laser scanning confocal microscope (SP5, Leica) with a 40X or 63X oil-
immersion objective. For LAMP1 (1:200, #L1418 Sigma-Aldrich) and EEA1 (1:500; 
#610457, BD Bioscience), ATP6V1B2 (1:200, #SAB1405501 Sigma-Aldrich) and 
LC3B (1:200, #2775 Cell Signalling) labeling, each image consisted of a stack of 
images taken through the z-plane of the cell. The colocalization of ATP6V1B2 and 
LC3B signals was analysed using the ImageJ intensity correlation analysis plugin to 
calculate Pearson’s correlation coefficient. For Lysotraker Deep Red (Molecular 
Probes/Life Technologies) experiments, HEK cells were incubated with 200 nM 
Lysotraker for 1 hr, whereas neurons were incuated with 50 nM Lysotraker for 30 
24 
 
min, at 37 °C in culture medium, immediately fixed and analysed within 12 hrs. 
Images were taken at either epifluorescence (Olympus 1X81) or confocal (SP5, 
Leica) microscope in a single plane not to fade the fluorescent signal. Settings were 
kept the same for all acquisitions within each experiment. 
 
Measurement of endo-lysosomal pH 
 
Endo-lysosomal pH was measured using a ratiometric pH indicator dye, Lysosensor 
Yelllow/Blue dextran (LYB-dx, Molecular Probes/Life Technologies), a dual 
excitation dye that allows pH measurement in endocytic organelles independently of 
dye concentration. Lymphoblasts (4 x 10
6
) were incubated for 3 hrs at 37 °C with 0.5 
mg/ml of LYB-dx in culture medium. Cells were divided into five samples, four to 
perform the calibration curve and one for the measures. To obtain a pH calibration 
curve, cells were resuspended with MES calibration buffer solution (5 mM NaCl, 115 
mM KCl, 1.2 mM MgSO4 and 25 mM MES, pH ranging from 3.7 to 7.6) containing 
10 M monensin (Sigma-Aldrich) and 10 μM nigericin (Sigma-Aldrich). For the pH 
measures, cells were resuspended in MES calibration buffer solution pH 7.7 in the 
absence of ionophores. Emission scans were collected at 450 nm and 528 nm with the 
Luminescence Spectrometer LS 50 (Perkin Elmer), using excitation at 360 nm and 
emission/excitation bandwidths set to 4 nm. Calibration data (ratio 450/528) were 
fitted to a linear regression with the software GraphPad Prism5 and the sample ratios 




Neurons were plated at low density (80 cells/mm
2
), transfected at 7 DIV and analysed 
at 10 DIV. For analysis, neurons were fixed in 4% PFA, in PBS and decorated with 
βIII tubulin antibody (1:1000, #MMS-435P Covance) followed by Alexa 488 
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secondary antibody to unequivocally distinguish neuronal cells. The extent of neurite 
arborization was evaluated using the Sholl analysis as previously described (Falace et 
al. 2010). Concentric circles with radii increasing at regular 10 μm steps were 
centered to the cell body and the number of intersections was automatically evaluated 




Neurons, plated at low density as described above, were either transfected at 14 DIV 
and analysed at 17 DIV or treated at 17 DIV with 200 nM leupeptin for 3 hrs (#EI8, 
MerckMillipore; Goo et al., 2017). To measure excitatory synapses, neurons were 
labeled with anti-V-GLUT1 (1/500, #135304; Synaptic Systems) and anti-Homer1 
(1/200, #160011; Synaptic Systems) antibodies. To measure inhibitory synapses, 
neurons were labeled with anti-V-GAT (1/500, #131004; Synaptic Systems) and anti-
Gephyrin (#147 011; Synaptic Systems) antibodies. Confocal images were acquired 
with a laser scanning confocal microscope (SP5 Upright, Leica) with a 40X oil-
immersion objective. Each image consisted of a stack of images taken through the z-
plane of the cell. Confocal microscope settings were kept the same for all scans in 
each experiment. The colocalization analysis was performed by evaluating the 
labeling of the VGLUT1/Homer1 and v-GAT/Gephyrin synaptic protein couples. 
Colocalization puncta with areas of 0.1-2 µm
2
 were considered bona fide synaptic 
boutons. Synaptic boutons along Cherry-positive neurites were manually counted on 











5.1 Mutations in v-ATPase subunit A in patients with developmental 
encephalopathy  
 
Through whole exome sequencing of a large cohort of children with 
neurodevelopmental disorder of presumed genetic origin, our collaborators have 
identified four different de novo missense mutations of the ATP6V1A gene in 
children with developmental encephalopathy featuring mental retardation and 
seizures,. All four de novo mutations caused missense substitutions at evolutionarily 





Figure 5. Multiple sequence alignment between human ATP6V1A and orthologous 
sequences. 
Residues affected by the missense substitutions are indicated by black arrows. 
 
 
5.2 Clinical findings 
 






In brief, early manifestations, observed in all patients, were developmental delay and 
febrile seizures, evolving to encephalopathies with profound delay, 
hypotonic/dyskinetic quadriparesis, intractable multiple seizure types and severe 
diffuse epileptiform EEG abnormalities in two patients [patient 1(p.Asp100Tyr) and 
patient 4(p.Asp371Gly)] and to moderate delay with milder epilepsy and 
focal/multifocal EEG abnormalities in the other two [patient 2(p.Asp349Asn) and 
patient 3(p.Asp371Gly)].  
Furthermore, the MRI images of the four patients can be seen below (Figure 6 to 






Figure 6. Patient 1 (p.Asp100Tyr)  
A-F shows six cuts of magnetic resonance imaging of the brain at 11 
years of age. Note the ventricular dilatation, with signs of mild cortical 
and cerebellar atrophy, a thin corpus callosum and hypomyelination in 





Figure 7. Patient 2 (p.Asp349Asn)  
Figures A-D shows four magnetic resonance imaging pictures of 






Figure 8. Patient 3 (p.Asp371Gly)  
Figures A-C show three magnetic resonance imaging pictures of the 






Figure 9. Patient 4 (p.Asp371Gly)  
Figures A-F shows six magnetic resonance imaging sections of the brain 
at 4 years of age. Note mild ventricular dilatation, with signs of mild 
cortical and cerebellar atrophy, a thin corpus callosum, hypomyelination 
in the posterior brain regions and plagiocephaly. 
 
5.3 Structural consideration of the v-ATPase mutations 
 
Our collaborators mapped the mutation sites of human ATP6V1A onto the crystal 
structure of the V1 domain from a prokaryotic homologue, Enterococcus hirae v-
ATPase. All the identified mutations fall into the A subunit of the V1 domain (Figure 
10A). 
 Pro12 (Pro27 in human ATP6V1A) resides in the type I -turn that is a part of the 
interaction interface between subunits A and B. Because the substitution of a proline 
residue with an arginine residue affects the main-chain conformation of the -turn, 
the mutation may perturb the A-B interaction (Figure 10 A, B). 
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Asp85 (Asp100 in human ATP6V1A) makes a hydrogen bond with Arg89, a 
guanidium group which makes van der Waals contacts with adjacent hydrophobic 
side chains (Figure 10 B). As a result, the side chain of Asp85 is closely surrounded 
by hydrophobic residues, and its replacement with a bulkier tyrosine residue quite 
likely causes steric hindrance and destabilizes the protein folding.  
Asp329 (Asp349 in human ATP6V1A) is located near a nucleotide-binding site 
(Figure 10 B) and its side chain is involved in water-mediated coordination with a 
magnesium ion, which plays a critical role in the ATPase activity (Figure 10 B). 
Thus, the Asp329Asn mutation possibly impairs the catalytic function. 
Asp351 (Asp371 in human ATP6V1A) is located at the interface among A, B and D 
subunits (Figure 10 A). The D subunit rotates within the A3B3 core along with the 
ATP hydrolysis, and thus the rotation process may be affected by the Asp351Gly 
mutation. The mutation sites were also mapped on the cryo-EM structure of the 
human homologue v-ATPase from the eukaryotic S. cerevisiae. As shown in Figure 
10 B, the mapped mutation sites in the S. cerevisiae structure overlap with those of 
the E. hirae, suggesting that the predicted impact of the mutations on the prokaryotic 





Figure 10. Structural mapping of the missense mutations in the V-ATPase. 
(A) Left: Crystal structure of the V1 domain from E. hirae v-ATPase in a nucleotide-bound 
state, viewed from the extracellular side (top) and the membrane plane (bottom), shown as 
the sphere representation. The A, B, D and F subunits are coloured in cyan, green, violet and 
brown, respectively, and residues at the mutation sites are coloured in red. The non-
hydrolyzable ATP analogue ANP (phosphoaminophosphonic acid-adenylate ester) is 
depicted as orange sticks. Right: Magnified views of the mutation sites presented in the 
ribbon model. Pro12 and Asp85 are depicted as red sticks, and Arg89, which makes a salt 
bridge with Asp85, is shown as sticks with translucent spheres. Some side chains of 
hydrophobic residues around Arg89 are shown as translucent spheres, and magnesium ion 
and its coordinated water molecules are depicted as a purple sphere and small grey dots, 
respectively. Black dotted lines indicate hydrogen bonds. Amino acid numbers in parentheses 
correspond to those of human ATP6V1A. (B) Crystal structures of the A subunit from E. hirae 
(orange) and the cryo-EM structure of the A subunit from S. cerevisiae (cyan, PDB code 
3J9T) V-ATPase. Mutation sites are shown as spheres and coloured in red for S. cerevisiae 




5.4 Effects of ATP6V1A mutations on protein expression and stability 
 
We addressed the impact of p.Asp349Asn and p.Asp100Tyr mutations on the 
ATP6V1A expression and stability by analysing HEK cells overexpressing 
ATP6V1A using a mammalian vector, driving the expression of the protein under the 
active human cytomegalovirus immediate early promoter (PCMV IE) as well as the 
expression of a cherry fluorescent tag to visualize transfected cells. Cells were 
transfected with vectors driving the expression of the wild type or mutant. 
Immunocytochemistry of transfected cells coupled with quantitative Western blot 
analysis showed a decreased expression of both ATP6V1A mutants that reached 
significance only for the p.Asp100Tyr variant, and no overt subcellular 
mislocalisation of both p.Asp100Tyr and p.Asp349Asn mutants with respect to wild 
type ATP6V1A (Figure11). The expression of the molecular partner, ATP6V1B2, 




Figure 11. Impact of ATP6V1A mutations on protein expression.  
(A) Representative images of HEK cells transfected with vectors coding wild-type ATP6V1A 
(w.t.), Asp349Asn ATP6V1A (Asp349Asn) or Asp100Tyr ATP6V1A (Asp100Tyr) variants. 
ATP6V1A immunolabelling, DAPI nuclear stain and Cherry reporter fluorescence are 
shown. Scale bar = 10 μm. (B) Representative western blot (left) from HEK cells transfected 
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as above and lysed 24 h after transfection. ATP6V1A and ATP6V1B2 intensities were 
quantified by densitometric analysis with respect to GAPDH intensity (right). Data are 
means ± standard error of the mean (SEM) from five independent experiments. *, p<0.05 
versus wild-type; Kruskall-Wallis/Dunn’s tests. 
 
To investigate the stability of ATP6V1A protein, we performed a degradation assay 
by treating transfected HEK cells with the protein synthesis inhibitor cycloheximide 
for various times. Compared to the wild type isoform, both mutant ATP6V1A 
isoforms were less stable, although degradation was significantly increased only for 
the p.Asp100Tyr variant (Figure 12).  
 
 
Figure 12. Impact of ATP6V1A mutations on protein stability.  
Left: Representative western blots of HEK cell lysates stained with anti-ATP6V1A antibody 
and anti-Gapdh as loading control. Cells were transfected with wild-type, Asp349Asn or 
Asp100Tyr ATP6V1A variants and incubated with cycloheximide for 2, 4, 8, 24 h or vehicle 
(DMSO; 24 h) as a control (–). Right: Densitometric analysis of ATP6V1A intensity with 
respect to GADPH expressed in percent of control samples without cycloheximide. Data are 
means ± SEM from four independent experiments. The areas under the respective curves 
were compared using the Kruskal-Wallis/Dunn’s tests. *, p<0.05 versus wild-type. 
 
We next asked whether these findings could also be observed in patients’ cells. To 
this aim, we analyzed the expression of endogenous ATP6V1A protein in patients’ 
lymphoblasts and compared it with the respective healthy parents' cells (Figure 13). 
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While the expression of ATP6V1A and ATP6V1B2 was not modified in Asp349Asn 
proband’s cells with respect to his healthy mother’s cells, a significant decrease of 
ATP6V1A, but not ATP6V1B2, expression was observed in Asp100Tyr proband’s 
cells. These data are in full agreement with the results in HEK cells and with the 
structural analysis prediction of a folding defect in the p.Asp100Tyr mutant (see 
Figure 10A) that may enhance its degradation. 
 
Figure 13. Analysis on ATP6V1A mutations in patients’ cells. 
(A) Representative western blot from lymphoblast lysates (30 μg) of patient affected by the 
Asp349Asn mutation (proband) and the healthy mother. (B) Representative western blot from 
lymphoblast lysates (30 μg) of patient affected by the Asp100Tyr mutation (proband) and the 
healthy mother. In A and B, ATP6V1A and ATP6V1B2 intensity were quantified by 
densitometric analysis with respect to GADPH. Data are means ± SEM from four 
independent experiments. *, p<0.05; Mann Whitney U-test. 
 
  
5.5 ATP6V1A mutations result in lysosomal abnormalities  
 
To examine the impact of the p.Asp349Asn and p.Asp100Tyr mutations in the 
regulation of pH homeostasis, we employed the Lysotraker probe to qualitatively 
evaluate intracellular acidic organelles. Before evaluating the pH of transfected cells, 
we validate the use of the sensor in our experimental model. To do this, we incubated 
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HEK293T with 200nM of LysoTracker for one hour, then we performed 
immunocytochemistry experiments. As shown in Figure 14, Lysosomes (Lamp-1 
positive puncta),correctly accumulated lysotracker signal. 
 
Figure 14. Validation of lysotracker protocol  
Representative images of HEK293 cells treated with LysoTracker deep red probe and 
immunolabeled with Lamp1. Scale bar = 10 μm. Merge panel indicates lysotracker 
signal is accumulated in lamp1 positive acidic organelles (lysosomes). 
 
Moreover we incubated HEK293T with 200nM of LysoTracker for one hour, then we 
added Bafilomycin 100nM, an inhibitor of v-ATPase, for an extra hour. As shown in 
Figure 15, there is a significant decrement of LysoTracker intensity in cells treated 








Figure 15: Bafilomycin, blocking v-ATPase activity, decreases lysotracker intensity 
(A) Cartoon showed how bafilomycin blocks v-ATPase activity. (B) Representative images of 
HEK293 cells labeled with LysoTracker deep red and LysoTracker deep red plus 
Bafilomycin. Graph shows quantification of fluorescent intensity from 17 cells for 
experimental group expressed as mean ± SEM. ****p<0.0001 with Student’t test. . Scale bar 
= 10 μm. 
 
We next analysed the impact of the p.Asp349Asn and p.Asp100Tyr mutations in the 
regulation of pH homeostasis in HEK cells overexpressing either pathogenic or wild 
type ATP6V1A variants. Interestingly, the p.Asp349Asn mutant showed an  
increased Lysotracker fluorescence intensity, while the p.Asp100Tyr mutant showed 
a decreased Lysotraker fluorescence intensity (Figure 16). 
 
Figure 16. Effect of ATP6V1A pathogenic variants on pH homeostasis  
Left: Representative images of HEK cells transfected with wild-type ATP6V1A (w.t.), 
Asp349Asn ATP6V1A (Asp349Asn) or Asp100Tyr, ATP6V1A (Asp100Tyr) variants and 
incubated with LysoTracker (200 nM, 1 h). Right: LysoTracker fluorescence intensity was 
quantified in 38 (wild-type), 41 (Asp349Asn) and 45 (Asp100Tyr) cells from three 
independent experiments. Individual data and means ± SEM are shown. *, p<0.05, 
****p<0.0001 versus wild-type; Kruskall-Wallis/Dunn’s tests. Scale bar = 10 μm. 
 
The Lysotraker signal monitors both the actual pH of acidic organelles, namely 
endosomal and lysosomal compartments, and their relative abundance within the cell. 
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Thus, we analyzed in parallel the expression of the endosomal and lysosomal 
markers, EEA1 and LAMP1, respectively. Whereas EEA1 expression was unaltered 
in HEK cells expressing wild type ATP6V1A or either pathogenic variants, the 
p.Asp100Tyr mutant was associated with a significant decrease of LAMP1 
expression evaluated by single-cell immunocytochemistry (Figure 17).  
 
Figure 17. Effects of ATP6V1A mutations on endo-lysosomal markers. 
Representative images and densitometric quantification from HEK cells transfected as above 
and immunolabelled with LAMP1 (left) or EEA1 (right). Histograms show quantification of 
signal intensity. Data are means ± SEM of 24–33 cells per experimental condition, from three 
independent experiments. ** p<0.01 versus wild-type Kruskall-Wallis/ Dunn’s tests. Scale 
bar = 10 μm. 
 
The data suggest that the p.Asp349Asn mutant exacerbates the acidic pH of the 
intracellular organelles, while the p.Asp100Tyr mutant leads to a decreased 
expression of LAMP1-positive lysosomal structures. Lysosomes also fuse with 
autophagosomal structures to generate autolysosomes and v-ATPase is responsible 
for the acidification of autolysosomal organelles. We therefore asked whether 
pathogenic ATP6V1A variants affect v-ATPase translocation to LC3-positive 
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phagosomal structures. To this aim, we measured the colocalization between the v-
ATPase subunit ATP6V1B2 and LC3 in HEK cells expressing wild type ATP6V1A 
or either pathogenic variants. Both p.Asp100Tyr and p.Asp349Asn resulted in a 
decreased colocalization coefficient with respect to wild type ATP6V1A (Figure 18). 
However, the activation of the autophagic flux by cell starvation-was slightly 
impaired by the p.Asp100Tyr mutation and substantially unaffected by the 
p.Asp349Asn mutation (Figure 18). 
 
 
Figure 18 Effects of ATP6V1A mutations on v-ATPase recruitment to autophagosomes. 
Representative images from HEK cells transfected as above and immunolabeled with 
ATP6V1B2 and LC3B under control conditions or after starvation for 2 hrs. Graph shows the 
quantification of ATP6V1B2 and LC3B colocalization using ImageJ software to determine 
the Pearson’s correlation coefficient. Data are means ± SEM of 30 cells per experimental 
condition. *, p<0.05 versus respective control; #, p<0.001 versus non-starved w.t.; §, 
p<0.001 versus starved w.t.. Data were analyzed by two-way ANOVA/ Bonferroni’s tests. 
Scale bar = 10 μm. 
 
 No significant changes in LC3II/LC3I ratio and p62 accumulation were observed in 
both experimental groups (Figure 19). The data suggest a significant impact of the 
two mutations on the recruitment of the v-ATPase to LC3-positive autolysosomal 
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Figure 19. Evaluation of LC3I/LC3II and p62 expression in HEK 
cells expressing wild type and pathogenic variants of ATP6V1A.  
Representative western blots from HEK cells treated as above. 
Immunoreactive bands for p62, LC3I, LC3II and Gapdh (loading 
control) are shown (left panel). Densitometric quantification of the 
LC3II/LC3I ratio and of p62 levels normalized to gapdh are shown 
(right panels). Data are means ± SEM of 5 experiments. 
 
To verify whether the alteration in lysosomal pH and levels of lysosomal markers 
were also present in patients, we subjected patients’ lymphoblasts to the same 
analysis. Experiments using the ratiometric pH probe Lysosensor Yelllow/Blue 
dextran (LYB-dx), revealed a significant reduction in endocytic organelle pH in the 
Asp349Asn patient’s lymphoblasts when compared to his healthy mother’s 
lymphoblasts, in the absence of any change in the expression of LAMP1 and EEA1 ( 
Figure 20 A). 
 Conversely, while the pH of endocytic organelles was not modified in the 
Asp100Tyr patient’s lymphoblasts, a significant reduction in LAMP1 expression was 





Figure 20. Effects of ATP6V1A mutations on intracellular organelle pH and 
endo-lysosomal markers in patients' cells 
A, Quantification of endocytic organelle pH in lymphoblasts from patients 
(probands) bearing either p.Asp349Asn (red) or p.Asp100Tyr (blue) mutation and 
the respective healthy mothers (black). Individual data and means± SEM of 5-6 
independent measurements are shown. *p<0.05; Wilcoxon matched pairs signed 
rank test. B, Representative western blot from lymphoblast lysates (30 μg) as 
defined above. LAMP1, EEA1 and Gapdh as loading control is shown. C, LAMP1 
and EEA1 immunoreactivities were quantified by densitometric analysis and 
normalized to Gapdh. Data are means ± SEM from four independent 
experiments. *p<0.05; Mann-Whitney U-test. 
 
Taken together these data suggest a gain-of-function effect for the p.Asp349Asn 
mutation, characterized by an increased proton pumping into intracellular organelles,  
and a loss-of-function effect for the p.Asp100Tyr mutation associated with defects in 




5.6 ATP6V1A mutations impact on neuronal pH homeostasis and neuronal 
development 
 
In view of the neurodevelopmental phenotype observed in the four patients carrying 
the de novo heterozygous ATP6V1A mutations, we investigated whether the effects on 
lysosomal homeostasis observed in HEK cells and patient-derived lymphoblasts were 
recapitulated in neurons. To address this question, we transiently expressed 
ATP6V1A and the pathogenic mutants in rat hippocampal neuronal cultures and 
evaluated intracellular acidic organelles by Lysotraker staining at the neuronal soma. 
As shown in Figure 21, neurons overexpressing p.Asp349Asn resulted in a 
significantly higher Lysotraker staining as compared to wild type ATP6V1A-
expressing neurons. On the opposite, p.Asp100Tyr ATP6V1A overexpression 
induced a significant loss of Lysotraker staining. Thus, the expression of the two 
mutants in neurons precisely phenocopies the effects observed in cell lines, 
suggesting that such an alteration in pH and lysosomal homeostasis also occurs in 









Figure 21. Effect of ATP6V1A mutations on pH homeostasis in primary hippocampal 
neurons.  
Left: Representative images of rat hippocampal neurons transfected with wild-type (w.t.), 
Asp349Asn (Asp349Asn) and Asp100Tyr (Asp100Tyr) ATP6V1A variants at 7 DIV and 
incubated with LysoTracker (50 nM, 30 min) at 10 DIV. Right: LysoTracker fluorescence 
intensity was quantified in 31 (wild-type), 28 (Asp349Asn) and 33 (Asp100Tyr) neurons from 
two independent preparations. Individual data and means ± SEM are shown. *p<0.05, 
**p<0.001 versus wild-type; Kruskall-Wallis/Dunn’s tests. Scale bar = 10 μm. 
 
To investigate cellular correlates of the patients' neurodevelopmental delay and 
explore whether the defects in Lysotraker signal have an impact on neuronal 
development, we transfected rat hippocampal neurons at 7 DIV and analyze neurite 
elongation at 10 DIV by Sholl analysis. The analysis revealed a similar and 
significant loss of neurite arborization for both p.Asp349Asn- and p.Asp100Tyr- 
expressing neurons, indicating that both pathogenic variants significantly affect the 
outgrowth and branching of neuronal processes during development (Figure 22). 
 
 
Figure 22. Effect of ATP6V1A mutations on development in primary hippocampal 
neurons.  
Left: Representative neurite traces of 10 DIV neurons transfected as in A. Right: Sholl 
analysis of neurite arborization as a function of distance from the soma. Data are means ± 
SEM of 29–33 neurons for experimental group from three independent preparations. ** 




5.7 ATP6V1A mutations affect synapse formation in primary neurons 
 
In developing neurons, neurite elongation is followed by synapse formation and 
stabilization. v-ATPase is a fundamental protein component of synaptic vesicles, 
where it allows neurotransmitter loading and regulates synaptic transmission 
(Takamori et al., 2006, Takamori, 2016). Moreover, acidic lysosomes have been 
recently described at excitatory postsynaptic sites (Goo et al., 2017; Padamsey et al., 
2017). Accordingly, the expression of the v-ATPase V1 subunits, ATP6V1A and 
ATP6V1B2, was found to increase in parallel with in vitro neuronal maturation and 




Figure 23. Expression of v-ATPase subunits in developing neurons.  
A. (Top) Representative rat hippocampal neurons, cultured on PLL, at DIV 
3. (Bottom). Representative rat hippocampal neurons, cultured on PLL, at 
DIV 14. Scale bar = 90 μm. B Representative western blot of rat 
hippocampal neuron lysates stained with: v-ATPase subunits, pre-synaptic 
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markers, post-synaptic markers at different days in vitro (DIV). Gapdh was 
used as loading control.  
 
To study the effects of ATP6V1A mutants on synapse formation, we transfected 
hippocampal neurons at 14 DIV and analyzed synapse density at 17 DIV. Excitatory 
synaptic contacts were visualized by double immunostaining with the excitatory 
presynaptic marker VGLUT1 and the excitatory postsynaptic marker Homer1 to 
unambiguously identify mature excitatory synapses. Synapse counting at 30 µm 
distance from the cell body revealed a significant loss of excitatory synaptic 
connections for p.Asp349Asn and p.Asp100Tyr overexpressing neurons, suggesting 
that both pathogenic variants dramatically impair the formation and maintenance of 
excitatory synapses (Figure 24).  
 
 
Figure 24. Effect of ATP6V1A mutations on excitatory synaptic connectivity in primary 
hippocampal neurons. 
Left panels: representative images of hippocampal neurons transfected with wild-type 
ATP6V1A (w.t.), Asp349Asn ATP6V1A (Asp349Asn) or Asp100Tyr ATP6V1A (Asp100Tyr) 
variants (top) at 14 DIV and analyzed at 17 DIV. White rectangles indicate proximal 
dendrites shown at high magnification in the bottom panels. Excitatory synaptic boutons 
were identified by double immunostaining for VGLUT1 (blue) and Homer1 (green). The 
colocalization panels (col. points) highlight the double-positive puncta (black), marked by 
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arrowheads, corresponding to bona fide synapses. The merge panels show positive puncta 
along transfected branches. Scale bar, 10 µm. Right panel: quantitative analysis of synaptic 
puncta counted on 30-µm branches starting from the cell body. Data are means ± SEM of 27-
28 neurons per experimental condition, from 3 independent preparations. ****p<0.0001 
versus w.t.; One-way ANOVA/Bonferroni’s tests. 
 
We further investigated the formation of inhibitory synapses. Neurons were 
transfected as above at 14 DIV and analyzed for synapse formation at 17DIV. 
Inhibitory synaptic contacts were visualized by double labeling with presynaptic 
marker v-GAT and postsynaptic marker Gephyrin, specific for inhibitory pre and post 
synaptic compartements. Co-localization puncta, representing mature GABAergic 
synapses, along transfected neurites, were automatically counted in the three 
experimental conditions. Unlike excitatory synapses, the number of inhibitory 
synapses was not affected by the expression of pathogenic variants (Figure 25). 
 
Figure 25. Effect of ATP6V1A mutations on inhibitory synaptic connectivity in primary 
hippocampal neurons. 
Left panels: representative images of hippocampal neurons transfected with wild-type 
ATP6V1A (w.t.), Asp349Asn ATP6V1A (Asp349Asn) or Asp100Tyr ATP6V1A (Asp100Tyr) 
variants (top) at 14 DIV and analyzed at 17 DIV. White rectangles indicate proximal 
dendrites shown at high magnification in the bottom panels. Inhibitory synaptic boutons were 
identified by double immunostaining for v-GAT (blue) and Gephyrin (green). The 
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colocalization panels (col. points) highlight the double-positive puncta (black), marked by 
arrowheads, corresponding to bona fide synapses. The merge panels show positive puncta 
along transfected branches. Scale bar, 10 µm. Right panel: quantitative analysis of synaptic 
puncta counted on 30-µm branches starting from the cell body. Data are means ± SEM of 27-
28 neurons per experimental condition, from 3 independent preparations. One-way 
ANOVA/Bonferroni’s tests. 
 
Interestingly, when we inhibited lysosomal function, treating hippocampal neurons 
with the lysosomal enzyme inhibitor leupetin , we found a similar effects on the 
density of excitatory synaptic contacts (Figure 26). 
 
 
Figure 26. Effects of leupeptin on the density of excitatory synapses. 
A: Representative images of hippocampal neurons at 14 DIV analyzed at 17 DIV under 
control conditions (ctrl) or treated with 200 µM leupeptin. Synaptic contacts were identified 
by double immunostaining for VGLUT1 and Homer1. The colocalization panels (col. points) 
highlight the double-positive puncta (white), corresponding to bona fide synapses. Scale bar, 
10 µm. B: Quantitative analysis of the density of excitatory synapses. Data are means ± SEM 
of 19 neurons per experimental condition, from 3 independent preparations. ***p<0.001 





The fact that leupeptin phenocopied the effects of the ATP6V1A pathogenic variants 
on synapse formation indicates that this effect may result from an alteration in 
lysosomal homeostasis that can be perturbed by both lysosome abundance or 
lysosomal pH.  
This is the first evidence of an effect of v-ATPase in synapse formation and suggests 
that pH homeostasis plays a fundamental role in the proper pre/postsynaptic coupling 
and that the pathogenic mutation possibly affect synaptogenesis in patient’s brain. 
We therefore studied the physiological role of ATP6V1A on neuronal development 
and synaptogenesis employing mRNA silencing strategy to model loss ATP6V1A 
expression in neuronal cell culture. 
The day of neuronal culture preparation (0 DIV) a suspension of dissected neurons 
were nucleofected either with a short-hairpin RNA(Sh-ATP6V1A), or its scrambled 
version (Scr-ATP6V1A) together with the TurboGFP as gene fluorescent report. We 
tested the effective knockdown of the protein by western blot analysis. We revealed a 
strong decreased expression of ATP6V1A at 5 DIV in Sh-ATP6V1A transfected 
neurons in respect to both not transfected and Scr-ATP6V1A transfected cells (Figure 
27 A). We also tested the knockdown of the protein also transfecting hippocampal 
neurons at 14 DIV and analyzed ATP6V1A expression level at 17 DIV using an 
antibody anti-ATP6V1A suitable for immunocytochemistry (ICC) (Figure 27 B). 
Also with ICC experiments, we revealed a strong decreased expression of ATP6V1A 




Figure 27. Evaluation of ATP6V1A knock down.  
(A) Representative western blots showing the effective ATP6V1A silencing in rat 
hippocampal neurons at 5DIV.(B) Representative images of rat hippocampal neurons 
transfected with Scr-ATP6V1A and Sh-ATP6V1A at 14 DIV and analysed at 17 DIV. Mean 
fluorescence intensity was quantified in 10 (Scr-ATP6V1A) and 8 (Sh-ATP6V1A) neurons. 
Individual data and means ± SEM are shown., **p<0.001 versus Scr-ATP6V1A, unpaired t 
test with Welch's correction. Scale bar = 20 μm. 
 
In view of the phenotype observed modelling the mutation found in the four patients 
with EOEE, we investigated whether the effects on lysosomal homeostasis were 
recapitulated in neurons silenced for ATP6V1A expression. We transiently silenced 
ATP6V1A in rat hippocampal neuronal cultures and evaluated intracellular acidic 
organelles by Lysotraker staining at the neuronal soma. As shown in Figure 28, 
neurons in which ATP6V1A was knocked down showed a significant loss of 
Lysotraker staining. Thus, the loss of ATP6V1A in neurons resulted an alteration in 




Figure 28. Effect of ATP6V1A knock down on pH homeostasis in primary hippocampal 
neurons.  
Left: Representative images of rat hippocampal neurons transfected with Scr-ATP6V1A and 
Sh-ATP6V1A at 14 DIV and incubated with LysoTracker (50 nM, 30 min) at 17 DIV. Right: 
LysoTracker fluorescence intensity was quantified in 33 (Scr-ATP6V1A) and 26 (Sh-
ATP6V1A) neurons from three independent preparations. Individual data and means ± SEM 
are shown.****p<0.0001 versus Scr-ATP6V1A, unpaired t test with Welch's correction. 
Scale bar = 20 μm. 
 
To investigate if the defects on Lysotraker signal have an impact on neuronal 
development, we transfected rat hippocampal neurons at 14 DIV and analyze neurite 
elongation at 17 DIV by Sholl analysis. The analysis revealed a similar and 
significant loss of neurite arborization observed with p.Asp100Tyr (the mutation 
impacting on ATP6V1A expressing level Figure 22) expressing neurons, indicating 
that the loss of ATP6V1A protein, causing an alteration on lysosomal homeostasis 
and pH, significantly affects the outgrowth and branching of neuronal processes 





Figure 29. Effect of ATP6V1A loss of expression on development in primary hippocampal 
neurons.  
Left: Representative images of rat hippocampal neurons transfected with Scr-ATP6V1A and 
Sh-ATP6V1A at 14 DIV and analyzed at 17 DIV Right: Sholl analysis of neurite arborization 
as a function of distance from the soma. Data are means ± SEM of 17 neurons for 
experimental group from three independent preparations. * p<0.01 versus Scr-ATP6V1A; 
unpaired t test with Welch's correction. Scale bar = 20 μm. 
 
A disfunction of lysosomal homeostasis and pH can impact on the autophagy being 
the lysosome the final destination for the engulfed materials of the autophagic 
process.  
Since the loss of ATP6V1A in neurons caused an alteration in pH and lysosomal 
homeostasis, we assessed the effect of ATP6V1A loss of expression on autophagic 
flux, by analyzing LC3II expression by western blot analysis. We transiently knocked 
down ATP6V1A in rat hippocampal neuronal cultures and analyzed the level of 
LC3II. We revealed a strong increased level of LC3II in Sh-ATP6V1A transfected 
neurons in respect to Scr-ATP6V1A transfected cells (Figure 30 A). Moreover ICC 
experiments revealed a strong increased expression of p62 in Sh-ATP6V1A 




Figure 30. The effect of ATP6V1A knock down on autophagic flux in primary 
hippocampal neurons.  
(A) Representative western blots showing the increased level of LC3II in Sh-ATP6V1A rat 
hippocampal neurons compared to Scr-ATP6V1A. (B) Representative images of rat 
hippocampal neurons transfected with Scr-ATP6V1A and Sh-ATP6V1A at 14 DIV and 
analysed at 17 DIV. P62 puncta were quantified in 22 (Scr-ATP6V1A) and 23 (Sh-ATP6V1A) 
neurons from three independent preparations. Individual data and means ± SEM are shown., 
**p<0.001 versus Scr-ATP6V1A, unpaired t test with Welch's correction. Scale bar = 20 μm.  
 
These data suggest that the loss of ATP6V1A in neurons caused a block of 
autophagic flux.  
How does this autophagic impairment impact on the excitatory synaptic boutons? To 
answer this question we investigated the effects of ATP6V1A loss of expression on 
synapse formation. We transfected hippocampal neurons at 14 DIV and analyzed 
synapse density at 17 DIV. Excitatory synaptic contacts were visualized by double 
immunostaining with the presynaptic marker VGLUT1 and the postsynaptic marker 
Homer1 to unambiguously identify mature excitatory synapses. Synapse counting at 
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30 µm distance from the cell body revealed a significant loss of excitatory synaptic 
connections in neurons transfected with Sh-ATP6V1A compared to Scr-ATP6V1A, 
suggesting that the loss of expression of ATP6V1A significantly impairs the 
formation and the maintenance of excitatory synapses (Figure 31). 
 
 
Figure 31. Effect of ATP6V1A loss of expression on excitatory synaptic connectivity in 
primary hippocampal neurons. 
left panels: representative images of proximal dendrites of hippocampal neurons transfected 
with Scr-ATP6V1A and Sh-ATP6V1A at 14 DIV and analyzed at 17 DIV. Excitatory synaptic 
boutons were identified by double immunostaining for VGLUT1 (blue) and Homer1 (Red). 
The colocalization panels (col. points) highlight the double-positive puncta (black), marked 
by arrowheads, corresponding to bona fide synapses. The merge panels show positive puncta 
along transfected branches. Scale bar, 10 µm. Right panel: quantitative analysis of synaptic 
puncta counted on 30-µm branches starting from the cell body. Data are means ± SEM of 12-
14 neurons per experimental condition, from 3 independent preparations. ****p<0.0001 




We showed the loss of ATP6V1A in neurons caused a block of autophagic flux 
(Figure 30). To associate that the decreased level of excitatory synaptic boutons, 
caused by the loss of expression of ATP6V1A, is due to an impairment of the 
autophagic flux, we used bafilomycin, an inhibitor of the vacuolar ATPase, which 
blocks the fusion of autophagosomes with lysosomes leading to an accumulation of 
autophagosomal structures (Yamamoto et al., 1998), to inhibits autophagic flux. 
Cultured primary cortical rat neurons were exposed to 300nM of bafilomycin for 8h 
and interestingly this treatment significantly increased LC3II and p62 signals 
phenocopies the results obtained with the knocked down ATP6V1A (Figure 32 A). 
Moreover, cultured primary cortical rat neurons were exposed to 100nM of 
bafilomycin for 1h and interestingly this treatment significantly decreased the number 
of excitatory synapses phenocopying the results obtained with the knocked down 
ATP6V1A (Figure 32 B) and demonstrating that the loss of ATP6V1A blocks 
autophagic flux and this effect causes a rearrangement of excitatory synapses. 
 
Figure 32. Block of autophagic flux on the density of excitatory synapses. 
A: representative Western Blot showing the increased level of LC3II and P62, in lysates of 
neurons exposed to 300 nM bafilomycin for 8h compared to neurons treated with DMSO as 
control. B: left panels: Representative images of hippocampal neurons at 17 DIV under 
control conditions (ctrl) or treated with 100 µM bafilomycin. Synaptic contacts were 
identified by double immunostaining for VGLUT1 and Homer1. The colocalization panels 
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(col. points) highlight the double-positive puncta (white), corresponding to bona fide 
synapses. Scale bar, 10 µm. Right panel: Quantitative analysis of the density of excitatory 
synapses. Data are means ± SEM of 19 neurons per experimental condition, from 3 
independent preparations. *p<0.05 versus ctrl.; Mann-Whitney U-test. 
 
6  Discussion 
 
The phenotypic features observed in the four patients reported here can be typically 
described as developmental encephalopathies with epilepsy and subsumed as 
ATP6V1A encephalopathy, although a larger number of observations is necessary to 
figure out the whole phenotypic spectrum. However, gathering a large series might 
require a long time since ATP6V1A mutations are very rare as they had not emerged 
before in large cohorts with epileptic and developmental encephalopathies (Allen et 
al. 2013, Appenzeller et al. 2014; Developmental Disorders Study 2017) and we 
could only identify four of them through WES studies on 1498 probands collected in 
three centers in Europe, Asia and the USA. 
Pathogenicity of the de novo p.Pro27Arg, p.Asp100Tyr, p.Asp349Asn and 
p.Asp371Gly variants could be established based on their occurrence in four patients 
with a developmental encephalopathy with epilepsy, their causing substitutions at 
highly evolutionarily conserved amino acid positions, their predicted highly 
damaging consequences emerging from in silico methods and the high intolerance of 
the ATP6V1A gene to variations. Accordingly, structural modelling allowed to 
localise the mutated sites in regions of ATP6V1A responsible for either the proper 
folding of the subunit (p.Asp100Tyr), the interaction with the V0 B subunit 




The many genes that have been associated with such complex developmental epilepsy 
conditions have revealed the pathogenic role of mutations affecting diverse molecular 
pathways that regulate ion channel functioning, membrane excitability, synaptic 
plasticity, neurotransmitter release, postsynaptic receptors, transporters, cell 
metabolism, and many formative steps in early brain development such as the 
proliferation and migration of neuronal precursors, dendritogenesis, synaptogenesis, 
cell and glial biology (Guerrini and Noebels, 2014). 
Our experimental work on the p.Asp100Tyr and p.Asp349Asn missense substitutions 
indicates that ATP6V1A mutations cause functional defects in v-ATPase physiology 
with alterations of lysosomal homeostasis associated with abnormal neuritogenesis 
and excitatory synaptic density.  
The main function of v-ATPase is proton transport and acidification of intracellular 
organelles, in particular lysosomes that have critical requirements for pH. The 
functional experiments performed on the p.Asp100Tyr mutation, causative of the 
more severe phenotype, demonstrated an increased degradation with impaired 
expression of ATP6V1A and a lower lysosomal abundance. This was also associated 
with a decreased recruitment of v-ATPase by autophagosomes under basal and 
starvation conditions, suggesting a potential impairment of the autophagic flux, as 
recently described in patients with mutation in the accessory v-ATPase subunit 
ATP6AP2 (Rujiano et al. 2017). Conversely, p.Asp349Asn, representative mutation 
for the milder phenotypes, resulted in decreased endo-lysosomal pH, with no effects 
on either expression of the mutant protein or lysosomal abundance, pointing to a gain 
of function effect. This variant slightly impairs v-ATPase translocation to 
autophagosomes under basal, but not starvation, conditions, suggesting that the 
formation of autolysosomes is preserved.  These functional findings were supported 
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by structural modeling results, predicting that the p.Asp100Tyr mutation decreases 
protein stability, whereas p.Asp349Asn affects the catalytic activity of v-ATPase. 
When modeled in hippocampal neurons, these pathogenic mutations produced the 
same significant and divergent effects on lysosomal intensity and endo-lysosomal pH 
that were observed in cell lines and probands' lymphoblasts, demonstrating the 
significance of the phenomena for the central nervous system. Moreover, in primary 
neurons, both p.Asp100Tyr and p.Asp349Asn mutants induced significant and 
comparable defects in dendrite development and excitatory synapse formation. 
This is the first evidence of an effect of v-ATPase in synapse formation and suggests 
that pH homeostasis plays a fundamental role in the proper pre/postsynaptic coupling 
and that the pathogenic mutation possibly affect synaptogenesis in patient’s brain. 
Considering the emerging role of excitatory/inhibitory balance in epileptic 
encephalopathy, we further measured GABAergic synapse formation in analogous 
system. Surprisingly both p.Asp100Tyr and p.Asp349Asn mutants did not affect the 
development of inhibitory synapses. This result suggests that either Glutamatergic 
synapse formation is more sensible to pH variation or that GABAergic synapse 
formation was already completed in the time frame we selected for the experiments. 
We favor the first hypothesis because western blot analysis revealed a drastic increase 
of both GABAergic (v-GAT) and glutamatergic (V-GLUT) presynaptic marker 
between 14 and 18 days in vitro, suggesting that the time interval was proper for both 
synaptic type. Interestingly, differences in vesicular pH between excitatory and 
inhibitory synapses have been recently reported: GABAergic synaptic vesicles exhibit 
a higher resting pH than glutamatergic synaptic vesicles (Egashira et al., 2016), and 
this difference may be at the basis of the observed phenotype.  
The neuronal phenotype of both mutants demonstrates a previously unexplored role 
of the v-ATPase in the processes of neuronal development and connectivity. As these 
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effects were phenocopied by leupeptin, a known inhibitor of lysosomal function, it is 
tempting to speculate that alterations in lysosomal homeostasis can bring about 
impairments in dendritogenesis and excitatory synapse formation. This hypothesis is 
also supported by recent reports on novel roles of lysosomes at the synapse for the 
turnover of synaptic proteins, as well as for the plasticity of dendritic spines (Sambri 
et al., 2017; Padamsey et al., 2017; Goo et al., 2017). Although the precise molecular 
mechanisms through which the described de novo mutations result in a developmental 
encephalopathy with epilepsy remain to be clarified, we here propose a role of 
alteration of lysosomal homeostasis as a novel pathogenic mechanism for 
epileptogenic developmental encephalopathy. Further work is needed to clarify the 
role of v-ATPase in brain development and to precisely establish the cellular 
signaling pathways that can be altered by loss of lysosomal homeostasis. 
Next generation sequencing studies have demonstrated that sporadic developmental 
disorders associated with epilepsy, once considered potentially recessive in nature, 
often arise from de novo mutations of dominant genes and that the same gene can be 
associated with a broader phenotypic spectrum than originally believed (Mei et al, 
2017). Our findings clearly link the ATP6V1A gene with a dominant form of 
encephalopathy after two biallelic homozygous missense mutations of the same gene 
had been related in three individuals to cutis laxa, a rare, severe systemic disorder, 
leading to early death in one of the patients and featuring, in addition to generalised 
skin wrinkling, marked hypotonia, dysmorphic facial features, cardiac abnormalities, 
structural brain abnormalities and seizures (Van Damme et al, 2017). Although 
comparison between our patients and the three previously reported with biallelic 
ATP6V1A mutations is only partially feasible, there is evidence that biallelic 
mutations cause a more complex phenotype in which severe neurological 
manifestations are part of a multiorgan involvement. A number of additional genetic 
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developmental disorders with epilepsy, including those related to PRRT2 (Ebrahimi-
Fakhari et al, 2015), TBC1D24 (Balestrini et al, 2016), RELN (Dazzo et al, 2015) and 
SLC2A1 (Wang et al, 2000) genes, have been associated with both autosomal 
dominant and more severe recessive phenotypes.  
Moreover we tried to elucidate why mutations on ATP6V1A can impact on formation 
and maintenance of excitatory synapses. 
V-ATPase is a proton transport important for the acidification of intracellular 
organelles, in particular lysosomes that have critical requirements for pH. This 
organelle contains enzymes active at the specific acidic pH, therefore when the 
lysosomal pH is not in correct range, the enzymatic function is inhibited. 
Autophagy is a cellular process that degrades proteins and organelles by delivering 
them to the lysosome. Three distinct type of autophagy have been described: 
Microautophagy, chaperone-mediated autophagy and macroautophagy (Kaushik and 
Cuervo 2012; Mizushima and Komatsu, 2011). Macroautophagy is characterized by 
the formation of the autophagosome, a double-membrane vesicle. that sequesters 
autophagic cargo and blends with a lysosome creating the autolysosomes in which the 
engulfed material is degraded by lysosomal enzymes. This scenario pointed out the 
central role of lysosomal pH, due to the activity of v-ATPase, in the autophagic 
pathway. 
Autophagy is an housekeeping process and it has a fundamental role in neuronal cells 
due to their post mitotic and long living nature. At synaptic level however the role of 
this catabolic process is only beginning to unravel. 
The synapse is a neuronal compartment important for the communication between 
neurons. At presynaptic site there is the quantal release of neurotransmitters into the 
synaptic cleft, while the post synaptic site contains a high density of receptors active 
by the neurotransmitter. 
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Emerging evidence suggests that autophagy is a mechanism with a central role at 
synaptic level in order to allow the synaptic transmission. A recent work elucidated 
that presynaptic protein Bassoon, that is a component of the synaptic active zone and 
crucial for the synaptic vesicles release (Ackermann et al., 2015), is crucial to inhibit 
autophagy in the presynaptic zone (Okerlund et al., 2018). Loss of Bassoon causes an 
increased number of autophagosomes in hippocampal neurons. Okerlund et al., 
proposed that Bassoon inhibits autophagy by interacting with Atg5, a protein crucial 
for the recruitment of LC3 to autophagosomes leading to an increased presynaptic 
autophagy with a decreased numbers of synaptic vesicles. This evidence suggests that 
autophagy flux degrades synaptic vesicles or their compartments. 
Recent work demonstrated autophagy plays an important role also on the postsynaptic 
site, especially in dendritic spines. Shehata et al. suggested autophagy locally 
degrades internalized AMPA receptors (Shehata et al., 2012). However it is unclear 
how it contributes to receptor degradation. It is possible that autophagy could degrade 
proteins involved for keeping receptors attached to the postsynaptic membrane. 
After demonstrating an effect of pathogenic mutation affecting one of the v-ATPase’s 
gene on synapse formation and moreover that pH homeostasis plays a fundamental 
role in the proper pre/postsynaptic coupling, in the last year of my PhD program we 
investigated on the role of v-ATPase on the autophagy and synaptic maintenance. 
In order to demonstrate the role of ATP6V1A on neuronal development and synaptic 
density, we showed a decreased expression of ATP6V1A using a short-hairpin RNA 
again ATP6V1A both with western blot and ICC experiments. This reduced level of 
protein was followed by the loss of function of v-ATPase in neurons evaluated as a 
lower level of lysotracker intensity meaning that there was an alteration in pH and 
lysosomal homeostasis. This alteration of lysosomal homeostasis and pH, due to the 
lack of expression of ATP6V1A, followed by a loss of function of this enzyme, 
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significantly affects the outgrowth and branching of neuronal processes during 
development. A disfunction of lysosomal homeostasis and pH impacts on the 
autophagic flux because of the central role of lysosome on macroautophagy. 
An experimental method to monitor autophagy is the detection of LC3 protein 
processing. LC3 proteins are specifically cleaved at the C terminus by Atg4 to 
become LC3-I, which then conjugates to phosphatidylethanolamine to form LC3-II 
(Kabeya et al., 2000). Based on the observation that LC3-II is degraded in 
autolysosomes, the level of LC3-II is used as a marker for the autophagic process 
(Klionsky et al., 2012). Autophagic flux can be detected by LC3-II turnover using 
Western blot analysis in the presence of lysosomal degradation inhibitors, such 
bafilomycin A1. The macrolide antibiotic bafilomycin A1 was among the first of this 
class isolated from Streptomyces gresius, and has been shown to be an inhibitor of the 
v-ATPase which controls pH in the lysosome (Browman et al., 1988; Yoshimori et 
al., 1991; Werner et al., 1984). Through this mechanism bafilomycin inhibits 
autophagic flux by preventing the acidification of endosomes and lysosomes 
(Klionsky et al.; 2008; Yamamoto et al.,1998). If autophagic flux is occurring, the 
level of LC3-II is increased in the presence of the lysosomal degradation inhibitor 
because the transit of LC3-II through the autophagic pathway is blocked. This 
scenario leads to a block of autophagic flux with an accumulation of LC3II signal. 
Moreover, during autophagy many types of cargo are degradated, P62, also known as 
Sequestosome‑1, is one factor that targets specific cargoes for autophagy (Lamark, 
2009). When autophagy is disrupted in several model systems, p62 accumulates. 
We assessed the effect of ATP6V1A loss of expression on autophagic flux and 
revealed strong increased level of LC3II followed by a strong increased expression of 
p62. We observed the same results when we treated wild type neurons with 
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bafilomycin. This correlation pointed out the central role of ATP6V1A on the 
autophagic flux in neuronal cells. 
As described above, autophagy as a central role in the brain so we moved to the 
synaptic level to study if the block of the autophagic flux could impact on the 
physiology of the excitatory synapses and demonstrated that the loss of expression of 
ATP6V1A dramatically impair the formation and maintenance of excitatory synapses. 
Collectively, these results suggest that the absence of a single subunit, ATP6V1A, of 
v-ATPase causes a dramatic lysosomal pH-dependent dysfunction leading to a block 
of the autophagic flux affecting both the neurodevelopmental process and the number 
of excitatory contacts. 
 
 
7 Future perspectives 
 
After we published the data, many clinicians contacted Prof. Renzo Guerrini and our 
group to inform on additional EOEE patients harboring mutations in ATP6V1A. Now 
we list 17 patients with 15 different de novo mutations in ATP6V1A. We mapped all 
the mutations in the human ATP6V1A modeled structure and revealed that they all 
cluster around the A/B interface and /or the A catalytic site. In the future, we plan to 
proceed to functionally characterize these novel  mutations in vitro using patient’s 
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Early infantile epileptic encephalopathy (EIEE) with a suppression burst 
electroencephalographic (EEG) pattern (also known as Ohtahara syndrome) is a 
severe condition with intractable seizures and profound developmental disability, 
starting in the first days or months of life. Using whole exome sequencing (WES), we 
identified homozygous and compound heterozygous mutations of the DMXL2 gene in 
six children, born from one non-consanguineous and two consanguineous families, 
exhibiting severe EIEE phenotypes associated with deafness, peripheral 
polyneuropathy and dysmorphic facial features, five of whom died in childhood. 
DMXL2 is highly expressed in the brain, regulates v-ATPase assembly and activity 
and participates in intracellular signalling pathways. The DMXL2 protein was absent 
in patient-derived skin fibroblasts, which exhibited an increased Lysotracker signal 
associated with decreased endo-lysosomal markers and impaired autophagy, an 
evolutionarily conserved lysosomal degradation process indispensable for cell 
homeostasis. The phenotype was recapitulated in Dmxl2-silenced mouse 
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Alpha-synuclein (αSyn) interferes with multiple steps of synaptic activity at pre-and 
post-synaptic terminals, however the mechanism/s by which αSyn alters 
neurotransmitter release and synaptic potentiation is unclear. By atomic force 
microscopy we show that human αSyn, when incubated with reconstituted membrane 
bilayer, induces lipid rafts' fragmentation. As a consequence, ion channels and 
receptors are displaced from lipid rafts with consequent changes in their activity. The 
enhanced calcium entry leads to acute mobilization of synaptic vesicles, and 
exhaustion of neurotransmission at later stages. At the post-synaptic terminal, an 
acute increase in glutamatergic transmission, with increased density of PSD-95 
puncta, is followed by disruption of the interaction between N-methyl-d-aspartate 
receptor (NMDAR) and PSD-95 with ensuing decrease of long term potentiation. 
While cholesterol loading prevents the acute effect of αSyn at the presynapse; 
inhibition of casein kinase 2, which appears activated by reduction of cholesterol, 
restores the correct localization and clustering of NMDARs. 
 
Gallotta I, Mazzarella N, Donato A, Esposito A, Chaplin JC, Castro S, Zampi G, 
Battaglia GS, Hilliard MA, Bazzicalupo P, Di Schiavi E. Neuron-specific knock-
down of SMN1 causes neuron degeneration and death through an apoptotic 
mechanism. Hum Mol Genet. 2016 Jun 15;25(12):2564-2577. 
 
Spinal muscular atrophy is a devastating disease that is characterized by degeneration 
and death of a specific subclass of motor neurons in the anterior horn of the spinal 
cord. Although the gene responsible, survival motor neuron 1 (SMN1), was identified 
20 years ago, it has proven difficult to investigate its effects in vivo. Consequently, a 
number of key questions regarding the molecular and cellular functions of this 
molecule have remained unanswered. We developed a Caenorhabditis elegans model 
77 
 
of smn-1 loss-of-function using a neuron-specific RNA interference strategy to 
knock-down smn-1 selectively in a subclass of motor neurons. The transgenic 
animals presented a cell-autonomous, age-dependent degeneration of motor neurons 
detected as locomotory defects and the disappearance of presynaptic and cytoplasmic 
fluorescent markers in targeted neurons. This degeneration led to neuronal death as 
revealed by positive reactivity to genetic and chemical cell-death markers. We show 
that genes of the classical apoptosis pathway are involved in the smn-1-mediated 
neuronal death, and that this phenotype can be rescued by the expression of human 
SMN1, indicating a functional conservation between the two orthologs. Finally, we 
determined that Plastin3/plst-1 genetically interacts with smn-1 to prevent 
degeneration, and that treatment with valproic acid is able to rescue the degenerative 
phenotype. These results provide novel insights into the cellular and molecular 
mechanisms that lead to the loss of motor neurons when SMN1 function is reduced. 
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plays a conserved role in the control of locomotion and ameliorates phenotypic 
defects in SMA models. Neurobiol Dis. 2017 Sep;105:42-50. + Equal contribution 
 
SMN (Survival Motor Neuron) deficiency is the predominant cause of spinal 
muscular atrophy (SMA), a severe neurodegenerative disorder that can lead to 
progressive paralysis and death. Although SMN is required in every cell for proper 
RNA metabolism, the reason why its loss is especially critical in the motor system is 
still unclear. SMA genetic models have been employed to identify several modifiers 
that can ameliorate the deficits induced by SMN depletion. Here we focus on 
WDR79/TCAB1, a protein important for the biogenesis of several RNA species that 
has been shown to physically interact with SMN in human cells. We show that 
WDR79 depletion results in locomotion defects in both Drosophila and 
Caenorhabditis elegans similar to those elicited by SMN depletion. Consistent with 
this observation, we find that SMN overexpression rescues the WDR79 loss-of-
function phenotype in flies. Most importantly, we also found that WDR79 
overexpression ameliorates the locomotion defects induced by SMN depletion in both 
flies and worms. Our results collectively suggest that WDR79 and SMN play 
78 
 
evolutionarily conserved cooperative functions in the nervous system and suggest that 
WDR79/TCAB1 may have the potential to modify SMA pathogenesis 
 
Leo D, Sukhanov I, Zoratto F, Illiano P, Caffino L, Sanna F, Messa G, Emanuele M, 
Esposito A, Dorofeikova M, Budygin EA, Mus L, Efimova EV, Niello M, Espinoza 
S, Sotnikova TD, Hoener MC, Laviola G, Fumagalli F, Adriani W, Gainetdinov RR. 
Pronounced Hyperactivity, Cognitive Dysfunctions, and BDNF Dysregulation in 
Dopamine Transporter Knock-out Rats. J Neurosci. 2018 Feb 21;38(8):1959-1972. 
 
Dopamine (DA) controls many vital physiological functions and is critically involved 
in several neuropsychiatric disorders such as schizophrenia and attention deficit 
hyperactivity disorder. The major function of the plasma membrane dopamine 
transporter (DAT) is the rapid uptake of released DA into presynaptic nerve terminals 
leading to control of both the extracellular levels of DA and the intracellular stores of 
DA. Here, we present a newly developed strain of rats in which the gene encoding 
DAT knockout Rats (DAT-KO) has been disrupted by using zinc finger nuclease 
technology. Male and female DAT-KO rats develop normally but weigh less than 
heterozygote and wild-type rats and demonstrate pronounced spontaneous locomotor 
hyperactivity. While striatal extracellular DA lifetime and concentrations are 
significantly increased, the total tissue content of DA is markedly decreased 
demonstrating the key role of DAT in the control of DA neurotransmission. 
Hyperactivity of DAT-KO rats can be counteracted by amphetamine, 
methylphenidate, the partial Trace Amine-Associated Receptor 1 (TAAR1) agonist 
RO5203648 ((S)-4-(3,4-Dichloro-phenyl)-4,5-dihydro-oxazol-2-ylamine) and 
haloperidol. DAT-KO rats also demonstrate a deficit in working memory and 
sensorimotor gating tests, less propensity to develop obsessive behaviors and show 
strong dysregulation in frontostriatal BDNF function. DAT-KO rats could provide a 
novel translational model for human diseases involving aberrant DA function and/or 
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De novo mutations of the ATP6V1A gene cause
developmental encephalopathy with epilepsy
Anna Fassio,1,2,* Alessandro Esposito,1,2,* Mitsuhiro Kato,3 Hirotomo Saitsu,4 Davide Mei,5
Carla Marini,5 Valerio Conti,5 Mitsuko Nakashima,4,6 Nobuhiko Okamoto,7 Akgun Olmez
Turker,8 Burcu Albuz,9 C. Nur Semerci Gündüz,9 Keiko Yanagihara,10 Elisa Belmonte,1
Luca Maragliano,2 Keri Ramsey,11 Chris Balak,11 Ashley Siniard,11 Vinodh Narayanan,11
C4RCD Research Group,11 Chihiro Ohba,6 Masaaki Shiina,12 Kazuhiro Ogata,12
Naomichi Matsumoto,6 Fabio Benfenati1,2 and Renzo Guerrini5,13
*These authors contributed equally to this work.
V-type proton (H + ) ATPase (v-ATPase) is a multi-subunit proton pump that regulates pH homeostasis in all eukaryotic cells; in
neurons, v-ATPase plays additional and unique roles in synapse function. Through whole exome sequencing, we identified de novo
heterozygous mutations (p.Pro27Arg, p.Asp100Tyr, p.Asp349Asn, p.Asp371Gly) in ATP6V1A, encoding the A subunit of v-
ATPase, in four patients with developmental encephalopathy with epilepsy. Early manifestations, observed in all patients, were
developmental delay and febrile seizures, evolving to encephalopathy with profound delay, hypotonic/dyskinetic quadriparesis and
intractable multiple seizure types in two patients (p.Pro27Arg, p.Asp100Tyr), and to moderate delay with milder epilepsy in the
other two (p.Asp349Asn, p.Asp371Gly). Modelling performed on the available prokaryotic and eukaryotic structures of v-ATPase
predicted p.Pro27Arg to perturb subunit interaction, p.Asp100Tyr to cause steric hindrance and destabilize protein folding,
p.Asp349Asn to affect the catalytic function and p.Asp371Gly to impair the rotation process, necessary for proton transport.
We addressed the impact of p.Asp349Asn and p.Asp100Tyr mutations on ATP6V1A expression and function by analysing
ATP6V1A-overexpressing HEK293T cells and patients’ lymphoblasts. The p.Asp100Tyr mutant was characterized by reduced
expression due to increased degradation. Conversely, no decrease in expression and clearance was observed for p.Asp349Asn. In
HEK293T cells overexpressing either pathogenic or control variants, p.Asp349Asn significantly increased LysoTracker fluores-
cence with no effects on EEA1 and LAMP1 expression. Conversely, p.Asp100Tyr decreased both LysoTracker fluorescence and
LAMP1 levels, leaving EEA1 expression unaffected. Both mutations decreased v-ATPase recruitment to autophagosomes, with no
major impact on autophagy. Experiments performed on patients’ lymphoblasts using the LysoSensorTM probe revealed lower pH
of endocytic organelles for p.Asp349Asn and a reduced expression of LAMP1 with no effect on the pH for p.Asp100Tyr. These
data demonstrate gain of function for p.Asp349Asn characterized by an increased proton pumping in intracellular organelles, and
loss of function for p.Asp100Tyr with decreased expression of ATP6V1A and reduced levels of lysosomal markers. We expressed
p.Asp349Asn and p.Asp100Tyr in rat hippocampal neurons and confirmed significant and opposite effects in lysosomal labelling.
However, both mutations caused a similar defect in neurite elongation accompanied by loss of excitatory inputs, revealing that
altered lysosomal homeostasis markedly affects neurite development and synaptic connectivity. This study provides evidence that
de novo heterozygous ATP6V1A mutations cause a developmental encephalopathy with a pathomechanism that involves perturb-
ations of lysosomal homeostasis and neuronal connectivity, uncovering a novel role for v-ATPase in neuronal development.
1 Department of Experimental Medicine, University of Genoa, Genoa, Italy
2 Center of Synaptic Neuroscience and Technology, Istituto Italiano di Tecnologia, Genoa, Italy
3 Department of Paediatrics, Showa University School of Medicine, Tokyo, Japan
doi:10.1093/brain/awy092 BRAIN 2018: 141; 1703–1718 | 1703
Received August 22, 2017. Revised January 26, 2018. Accepted February 10, 2018. Advance Access publication April 13, 2018
 The Author(s) (2018). Published by Oxford University Press on behalf of the Guarantors of Brain.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits
non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
4 Department of Biochemistry, Hamamatsu University School of Medicine, Hamamatsu, Japan
5 Pediatric Neurology, Neurogenetics and Neurobiology Unit and Laboratories, Children’s Hospital A. Meyer-University of
Florence, Florence, Italy
6 Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan
7 Department of Medical Genetics, Osaka Women’s and Children’s Hospital, Osaka, Japan
8 Private Clinic, Denizli, Turkey
9 Department of Medical Genetics, Pamukkale University Hospital, Denizli, Turkey
10 Department of Paediatric Neurology, Osaka Women’s and Children’s Hospital, Osaka, Japan
11 Center for Rare Childhood Disorders and Neurogenomics Division Translational Genomics Research Institute, Phoenix, Arizona
85004, USA
12 Department of Biochemistry, Yokohama City University Graduate School of Medicine, Yokohama, Japan
13 IRCCS Fondazione Stella Maris, Pisa, Italy
Correspondence to: Prof. Renzo Guerrini
Neuroscience Department, Anna Meyer Children’s University Hospital, Florence Italy
E-mail: r.guerrini@meyer.it
Correspondence may also be addressed to: Prof. Anna Fassio
Department of Experimental Medicine, University of Genoa, Italy
E-mail: afassio@unige.it
Prof. Naomichi Matsumoto
Department of Human Genetics, Yokohama City University, Japan
E-mail: naomat@yokohama-cu.ac.jp
Keywords: developmental epileptic encephalopathy; v-ATPase; lysosomes; neurite elongation; synapse
Abbreviations: DIV = days in vitro; v-ATPase = v-type proton (H + ) ATPase
Introduction
V-type proton (H + ) ATPase (v-ATPase) is a multimeric
complex that acts as an ATP-dependent proton pump.
V-ATPase is composed of a peripheral V1 domain that
hydrolyses ATP and an integral V0 domain that translo-
cates protons by a rotary mechanism. V-ATPase is
responsible for membrane trafficking processes such as re-
ceptor-mediated endocytosis, intracellular trafficking of
lysosomal enzymes, and acidification of intracellular organ-
elles in all eukaryotic cells (Forgac, 2007; Cotter et al.,
2015). Despite the ubiquitous role in pH homeostasis and
intracellular signalling pathways, the v-ATPase complex is
expressed at high levels in neurons where it plays add-
itional and unique roles in neurotransmitter loading into
synaptic vesicles and in regulating synaptic transmission
(Morel and Poëa-Guyon, 2015; Bodzeta et al., 2017).
In humans, a redundant set of subunits is encoded by
22 autosomal genes, allowing the composition of diverse v-
ATPase complexes with specific properties and tissue
expression. Among these, seven have been associated with
human disease (Supplementary Table 1). Six subunits have
been related to recessive disorders, including distal renal
tubular acidosis and hearing loss (ATP6V1B1 and
ATP6V0A4) (Karet et al., 1999; Smith et al., 2000; Stover
et al., 2002), osteopetrosis with macrocephaly, progressive
deafness, blindness, hepatosplenomegaly, and severe anaemia
(ATP6V0A3) (Frattini et al., 2000; Kornak et al., 2000), and
cutis laxa, a systemic disease with severe neurological im-
pairment featuring structural brain abnormalities, profound
delay, and seizures (ATP6V0A2, ATP6V1E1 and ATP6V1A)
(Kornak et al., 2008; Fischer et al., 2012; Van Damme et al.,
2017). Two allelic dominant disorders, Zimmermann-
Laband syndrome type 2, featuring facial dysmorphisms
and intellectual disability (Kortum et al., 2015) and a form
of congenital deafness with anonyochia, have also been
described (ATP6V1B2) (Yuan et al., 2014).
Through whole exome sequencing of 1444 patients with
developmental encephalopathies and epilepsy, we identified
in four patients heterozygous de novo missense mutations
in ATP6V1A (p.Pro27Arg, p.Asp100Tyr, p.Asp349Asn,
p.Asp371Gly), all involving highly evolutionarily conserved
residues in functionally relevant regions of the molecule.
Functional analysis conducted for the p.Asp100Tyr and
p.Asp349Asn mutations demonstrated a loss-of-function
mechanism involving increased ATPase degradation and
lysosomal defects for the former, and a gain-of-function
mechanism consisting of increased acidification of intracel-
lular organelles for the latter. In neurons, both ATP6V1A
mutants caused a defect in neurite elongation, accompanied
by a significant loss of excitatory synapses, suggesting a
crucial and unexplored role of v-ATPase in neuronal devel-
opment and synapse formation. We provide evidence that
de novo heterozygous ATP6V1A mutations cause a devel-
opmental encephalopathy with epilepsy with a pathome-
chanism that involves the effects of v-ATPase in
lysosomal homeostasis and neuronal connectivity. This
study also demonstrates that ATP6V1A mutations can be
disease causing at the heterozygous state, although previ-
ously described biallelic phenotypes are more severe.
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Patients and methods
Patients
Exome studies were conducted in three cohorts, including pa-
tients of different ethnicities (Supplementary Table 2A), with
developmental delay/intellectual disability and epilepsy of pre-
sumed genetic origin. The overall series consisted of 1444 pro-
bands, most of whom were part of a trios study. Patients were
assigned to eight specific epileptic encephalopathy syndromes,
plus a ninth subgroup of ‘unclassified’ epileptic encephalopa-
thies with mixed seizure disorders that could not be assigned
to a specific syndrome (Supplementary Table 2B). All four
patients with ATP6V1A mutations belonged to the latter
subgroup.
All participants to the study had signed an informed consent
for research whole exome sequencing studies. The study was
approved by the Paediatric Ethic Committee of the Tuscany
Region, in the context of the DESIRE project (Seventh
Framework Programme FP7; grant agreement n 602 531).
Whole exome sequencing
In 900 patients, whole exome sequencing was performed with
the SureSelectXT Human All Exon v5 or v6 (Agilent
Technologies). Captured libraries were sequenced using
Illumina Hiseq 2500 (Illumina) with 101-base paired-end
reads. Exome data processing, variant calling, and variant an-
notation were performed as previously described (Saitsu et al.,
2013). In singleton probands exhibiting de novo mutations,
parentage was confirmed by microsatellite analysis, as previ-
ously described (Saitsu et al., 2013). In 494 patients, whole
exome sequencing was performed and analysed as previously
described (Narayanan et al., 2015). In 50 additional patients,
exons were captured from fragmented genomic DNA samples
using the SureSelect Human All Exon v4 (Agilent
Technologies), and paired-end 90-base massively parallel
sequencing was carried out on an Illumina HiSeq 2000, ac-
cording to the manufacturer’s protocols (Illumina). In the latter
group, bioinformatics analysis was carried out using an in-
house developed pipeline. Sequencing reads passing quality fil-
tering were aligned to the human reference genome (hg19)
with Burrows-Wheeler Aligner (BWA) (Li and Durbin,
2010). The Genome Analysis Toolkit (GATK) (McKenna
et al., 2010) was used for base quality score recalibration,
indel realignment, duplicate removal, and to perform SNP
and INDEL discovery and genotyping across all samples sim-
ultaneously using variant quality score recalibration according
to GATK Best Practices recommendations (DePristo et al.,
2011; Van der Auwera et al., 2013). For annotating and fil-
tering data, the SNPeff program was used (Cingolani et al.,
2012). The de novo variants were called using the
DeNovoGear tool with a 0.8 threshold at the posterior prob-
ability of the most likely de novo genotype configuration
(Ramu et al., 2013). All samples had a mean depth of target
region covered at 112 and 497% of bases in the consensus
coding sequences covered by at least 20 reads. We excluded
variants with minor allele frequency (MAF) 41% in either the
1000 Genomes Project (1000g) or the Exome Aggregation
Consortium (ExAC v0.3) databases.
In patients carrying ATP6V1A variants, we excluded de
novo or recessive (MAF51%) variants in the well-established
genes for epileptic encephalopathies (listed in Supplementary
Table 3) and submitted for validation and segregation testing
by Sanger sequencing of candidate de novo variants that were
predicted to alter protein function (non-synonymous, stop-
gain, stop-loss, frameshift, and splice-junction mutations).
We evaluated whether the ATP6V1A human protein-coding
gene is likely to harbour disease-causing mutations using dif-
ferent gene-level prediction tools including the ExAC (Exome
Aggregation Consortium) constraint metrics (Lek et al., 2016),
the residual variation intolerance score (RVIS; based on ExAC
v2 release 2.0) (Petrovski et al., 2013) and the gene damage
index (GDI) (Itan et al., 2015). Furthermore, to improve the
use of existing variant-level methods such as the Combined
Annotation Dependent Depletion (CADD) score (Kircher
et al., 2014) and test the four missense substitutions we iden-
tified in ATP6V1A, we also used the mutation significance cut-
off (MSC) server (Itan et al., 2016), a quantitative approach
that provides gene-level and gene-specific phenotypic impact
cut-off values.
We evaluated mutations’ pathogenicity for the four
ATP6V1A variants through in silico prediction using the
dbNSFP database (v3.0a), which provides functional predic-
tion scores on more than 20 different algorithms (https://
sites.google.com/site/jpopgen/dbNSFP). To assess the effects
of the four missense ATP6V1A substitutions, we used both
the dbNSFP ensemble rank scores MetaSVM and MetaLR
(Liu et al., 2016). In addition, we used the scores obtained
from Revel (Ioannidis et al., 2016), M-CAP (Jagadeesh et al.,
2016) and Eigen (Ionita-Laza et al., 2016), three different bio-
informatics tools to evaluate the pathogenicity of rare variants.
We performed conservation analysis across species (ortholo-
gous sequences) using a multiple sequence alignment (MSA) of
the ATP6V1A protein sequence. The MSA (MUSCLE algo-
rithm) and the sequence logo consensus were generated by
the Jalview software (http://www.jalview.org). Residues were
coloured according to their physicochemical properties
(Zappo colour scheme).
To evaluate if de novo ATP6V1A variants had ever been
reported, either in affected individuals or controls, we interro-
gated the denovo-db database (Turner et al., 2017).
ATP6V1A gene de novo mutation
enrichment analysis
To assess whether in the 1444 probands cohort the ATP6V1A
gene was enriched in missense de novo mutations, we used the
freely available R package DenovolyzeR (Ware et al., 2015)
and gene-specific mutation rates originally reported by
Samocha et al. (2014). The ATP6V1A de novo gene-specific
P-value calculated by DenovolyzeR for missense variants was
corrected for multiple testing (Bonferroni correction), accord-
ing to the 19 618 genes for which mutation rates are available,
and the number of tests (one test for the missense class). The
genome-wide Bonferroni corrected P-value threshold at
a = 0.05 for one test was 2.55  106 [0.05/(1  19 168)].
We carried out the ATP6V1A de novo mutation enrichment
analysis in the overall cohort without any stratification using
the RStudio software (rstudio.com).
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To rule out that the four variants could have arisen by
chance, we performed the chi-squared test with Yates correc-
tion for a 2  2 contingency table (patients carrying the vari-
ants/mutation negative patients versus controls carrying the
variants/mutation negative controls) using the QuickCalcs
tool (graphpad.com/quickcalcs/contingency1.cfm). For each
variant, we carried out the test on exome data of our cohort
and the Genome Aggregation Database (gnomAD) cohorts,
both at large and through ethnicity-matched analysis.
Structural modelling
We searched the crystal structure homologous to human
ATP6V1A using the protein homology/analogy recognition
engine, Phyre2 (Kelley et al., 2015). We calculated the free
energy change upon the Asp85Tyr mutation with the FoldX
software (foldxsuite.crg.eu) using the crystal structure of the
V1 domain from Enterococcus hirae v-ATPase in a nucleotide-
bound state (PDB code 3VR6). The molecular structures were
drawn using PyMOL (Schrödinger, New York, NY). Using the
same Phyre2 server, we also obtained the alignment of human
ATP6V1A and Saccharomyces cerevisiae A subunit primary
sequences. The homology model was created using I-TASSER
(Roy et al., 2010), with the A subunit of S. cerevisiae v-ATPase
(PDB code 3J9T) as template.
ATP6V1A constructs
We synthesized wild-type and mutant (p.Asp100Tyr and
p.Asp349Asn) human ATP6V1A cDNAs in vitro and cloned
in pLVX-IRES-mCherry vector by Biomatik. We performed
Sanger sequencing of all constructs to check the correct inserts
orientation and validate their sequence.
Cell culture and transfection
Human embryonic kidney-derived 293T (HEK) cells were
maintained at 37C in a humidified 5% CO2 incubator in
DMEM (Life Technologies) supplemented with 10% FBS,
2 mM L-glutamine and 1% Penicillin-Streptomycin. Cells
were transfected with Lipofectamine 2000 (Life Technologies)
according to the manufacturer’s instructions. HEK cells were
starved by medium withdrawal for 2 h. Lymphoblatsts were
prepared by infecting lymphocytes obtained from patients
and their parents with the Epstein-Barr virus (EBV) in vitro
using standard protocols and maintained in RPMI 20% foetal
bovine serum (FBS), 1 mM L-glutamine and 10 mM D-glucose.
Primary cortical neurons were prepared from embryonic Day
18 brains of Sprague Dawley rats as previously described
(Verstegen et al., 2014). Neurons were transfected using
Lipofectamine 2000 at 7 or 14 days in vitro (DIV) and ana-
lysed 3 days after transfection.
Western blotting
Protein lysates from HEK, lymphoblast and neuronal cultures
were extracted in lysis buffer [50 mM Tris (pH 7.5), 150 mM
NaCl, 0.1% SDS, 1% Nonidet P40, 0.2 mM phenylmethylsul-
fonyl fluoride, 2mg/ml pepstatin, and 1mg/ml leupeptin] and
then separated by SDS-PAGE and assayed by immunoblotting
with the following primary antibodies: anti-ATP6V1A
(1:1000; #ab137574, Abcam), anti-ATP6V1B2 (1:2000;
#ab73404, Abcam), anti-LAMP1 (1:1000; #ab24170,
Abcam), anti-EEA1 (1:5000; #610457, BD Bioscience), LC3B
(1:1000; #7543, Sigma-Aldrich), p62 (1:1000, #P0067, Sigma-
Aldrich), anti-GAPDH (1/1000; #SC-25778, Santa Cruz
Biotechnology), anti-VAMP2 (1:1000; #104202; Synaptic
Systems); anti-V-GLUT1 (1:1000; #135304, Synaptic
Systems) anti-PSD95 (1:1000; #SC-32290, Santa Cruz
Biotechnology).
Degradation assay
HEK cells were transfected with ATP6V1A wild-type,
ATP6V1A Asp349Asn or ATP6V1A Asp100Tyr and treated
with 10 mg/ml of cycloheximide (C4859, Sigma-Aldrich) 24 h
after transfection. Cells were lysed at different times after
cycloheximide addition and analysed by western blotting.
Protein level is expressed with respect to ATP6V1A content




Transfected primary cortical neurons or HEK cells were fixed
in 4% paraformaldehyde in phosphate-buffered saline (PBS),
permeabilized in 0.1% TritonTM X-100, blocked with 2%
FBS/0.05% Tween-20 in PBS and incubated with the various
antibodies in blocking solution. Samples were mounted in
ProLong Gold antifade reagent with DAPI (#P36935,
Thermo-Fisher Scientific). Capture of confocal images was per-
formed using a laser scanning confocal microscope (SP5, Leica)
with a 40 or 63 oil-immersion objective. For LAMP1
(1:200, #L1418 Sigma-Aldrich) and EEA1 (1:500; #610457,
BD Bioscience), ATP6V1B2 (1:200, #SAB1405501 Sigma-
Aldrich) and LC3B (1:200, #2775 Cell Signalling) labelling,
each image consisted of a stack of images taken through the
z-plane of the cell. The co-localization of ATP6V1B2 and
LC3B signals was analysed using the ImageJ intensity correl-
ation analysis plugin to calculate Pearson’s correlation coeffi-
cient. For LysoTracker Deep Red (Molecular Probes/Life
Technologies) experiments, HEK cells were incubated with
200 nM LysoTracker for 1 h, whereas neurons were incu-
bated with 50 nM LysoTracker for 30 min, at 37C in culture
medium, immediately fixed and analysed within 12 h. Images
were taken at either epifluorescence (Olympus 1X81) or con-
focal (SP5, Leica) microscope in a single plane not to fade the
fluorescent signal. Settings were kept the same for all acquisi-
tions within each experiment.
Measurement of endo-lysosomal pH
Endo-lysosomal pH was measured using a ratiometric pH in-
dicator dye, LysoSensorTM Yellow/Blue dextran (Molecular
Probes/Life Technologies), a dual excitation dye that allows
pH measurement in endocytic organelles independently of
dye concentration. Lymphoblasts (4  106) were incubated
for 3 h at 37C with 0.5 mg/ml of LysoSensorTM Yellow/Blue
dextran in culture medium. Cells were divided into five sam-
ples, four to perform the calibration curve and one for the
measurements. To obtain a pH calibration curve, cells were
resuspended with MES calibration buffer solution
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(5 mM NaCl, 115 mM KCl, 1.2 mM MgSO4 and 25 mM MES,
pH ranging from 3.7 to 7.6) containing 10 mM monensin
(Sigma-Aldrich) and 10 mM nigericin (Sigma-Aldrich). For the
pH measures, cells were resuspended in MES calibration buffer
solution pH 7.7 in the absence of ionophores. Emission scans
were collected at 450 nm and 528 nm with the Luminescence
Spectrometer LS 50 (Perkin Elmer), using excitation at 360 nm
and emission/excitation bandwidths set to 4 nm. Calibration
data (ratio 450/528) were fitted to a linear regression with
the software GraphPad Prism5 and the sample ratios converted
into absolute pH values by interpolation in the calibration
function.
Sholl analysis
Neurons were plated at low density (80 cells/mm2), transfected
at 7 DIV and analysed at 10 DIV. For analysis, neurons were
fixed in 4% PFA, in PBS and decorated with bIII tubulin anti-
body (1:1000, #MMS-435P Covance) followed by Alexa
Fluor 488 secondary antibody to unequivocally distinguish
neuronal cells. The extent of neurite arborization was evalu-
ated using Sholl analysis as previously described (Falace et al.,
2010). Concentric circles with radii increasing at regular 10-
mm steps were centred to the cell body and the number of
intersections was automatically evaluated with the ImageJ/
Sholl analysis plug-in.
Synapse quantification
Neurons, plated at low density as described above, were either
transfected at 14 DIV and analysed at 17 DIV or treated at 17
DIV with 200 nM leupeptin for 3 h (#EI8, MerckMillipore;
Goo et al., 2017). To measure excitatory synapses, neurons
were labelled with anti-V-GLUT1 (1/500, #135304; Synaptic
Systems) and anti-Homer1 (1/200, #160011; Synaptic Systems)
antibodies. Confocal images were acquired with a laser scan-
ning confocal microscope (SP5 Upright, Leica) with a 40 oil-
immersion objective. Each image consisted of a stack of images
taken through the z-plane of the cell. Confocal microscope
settings were kept the same for all scans in each experiment.
The co-localization analysis was performed by evaluating the
labelling of the VGLUT1/Homer1 synaptic protein couples.
Co-localization puncta with areas of 0.1–2 mm2 were con-
sidered bona fide synaptic boutons. Synaptic boutons along
Cherry-positive neurites were manually counted on 30 mm
puncta starting from the cell body.
Results
Identification of ATP6V1A mutations
Trio-based whole exome sequencing studies revealed de
novo mutations in ATP6V1A (MIM 607 027; RefSeq ac-
cession number NM_001690.3), encoding the ATPase H +
transporting V1 subunit A in three patients [Patient 1:
c.298G4T (p.Asp100Tyr); Patient 2: c.1045G4A
(p.Asp349Asn); and Patient 4: c.80C4G (p.Pro27Arg)].
A subsequent search for ATP6V1A variants in whole
exome sequencing data obtained from singleton patients,
identified an additional patient carrying a de novo
heterozygous ATP6V1A variant [Patient 3: c.1112A4G
(p.Asp371Gly)]. Patients 1–3 were identified via an ongoing
collaboration matching exome data generated in Europe by
the DESIRE project on rare developmental/epileptic ence-
phalopathies (http://epilepsydesireproject.eu) with those of
a comparable cohort in Japan. Patient 4 was subsequently
identified through DESIRE dissemination activities, after
preliminary data on the first three patients were made
available in the project website. We also screened for
ATP6V1A inherited variants with a frequency 51% in
the 1000 Genomes Project (1000g) or in the Exome
Aggregation Consortium (ExAC) databases, both in cases
of homozygous recessive or compound heterozygous state.
None of the de novo ATP6V1A identified mutations was
observed in the 1000g, ExAC, gnomAD or dbSNP (build
147) databases. We confirmed the mutations and their de
novo nature on genomic DNA of probands and parents by
Sanger sequencing. Patient 3 parentage was confirmed
using 12 microsatellite markers.
All four highly functionally relevant de novo mutations
caused missense substitutions at evolutionarily conserved
amino acid positions (Fig. 1) and were predicted to be dama-
ging by in silico methods (Supplementary Table 4A). ExAC
constraint metrics indicated that ATP6V1A has fewer vari-
ants than expected and is intolerant both to loss-of-function
(pLI = 0.99) and missense variants (Z-score = 3.03). The
RVIS (RVIS score 0.7; RVIS percentile 20.93%) and the
GDI (GDI score 22.7; GDI_Phred 0.76) scores also highlight
ATP6V1A intolerance to variations. Finally, the MSC
damage prediction (99% confidence interval) tool highlights
the highly damaging impact the p.Pro27Arg, p.Asp100Tyr,
p.Asp349Asn, and p.Asp371Gly substitutions have on the
ATP6V1A protein, according to the MSC CADD corrected
scores (Supplementary Table 4B).
To explore pathogenicity of the four variants further, we
performed gene-specific de novo mutation enrichment ana-
lysis and a variant-specific chi-squared test with Yates cor-
rection for a 2  2 contingency table. The ATP6V1A
missense de novo mutations enrichment analysis performed
with DenovolyzeR (n = 1444, de novo mutations
observed = 4, de novo mutations expected = 0.1, enrich-
ment 79) reached genome-wide statistical significance
(P-value of 2.63  107; Bonferroni correct threshold P-
value 2.55  106). All four variants reached significant
values (P5 0.0001) in the chi-squared test performed
using the 123 136 gnomAD exomes as control
(Supplementary Table 5A). Performing the same analysis
matching the four mutations versus ethnically matched sub-
populations, all mutations maintained significant values
(Supplementary Table 5B–E). These data suggest that the
ATP6V1A mutations did not occur by chance in the cohort
studied.
The denovo-db returned only five de novo hits (three
intronic and two missense substitutions) in ATP6V1A.
The two missense substitutions were p.Asp11Asn, identified
in a male with autism spectrum disorder (Iossifov et al.,
2014), and p.Pro249Arg identified in another male with a
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severe developmental disorder (McRae et al., 2017). These
two missense substitutions, however, have not been sub-
jected to orthogonal validation and should therefore be
considered as ‘potential’ de novo variants. These data fur-
ther highlight how rare de novo mutations are in the
ATP6V1A gene.
Clinical findings
Clinical, EEG and MRI findings observed in the four pa-
tients are summarized in Table 1 and presented in detail in
the Supplementary material. In brief, early manifestations,
observed in all patients, were developmental delay and fe-
brile seizures, evolving in two patients to encephalopathy
with profound delay, hypotonic/dyskinetic quadriparesis,
intractable multiple seizure types and severe diffuse epilepti-
form EEG abnormalities (Patients 1 and 4) and to moderate
delay with milder epilepsy and focal/multifocal EEG
abnormalities in the other two (Patients 2 and 3).
Structural consideration of the
v-ATPase mutations
We mapped the mutation sites of human ATP6V1A onto
the crystal structure of the V1 domain from a prokaryotic
homologue, E. hirae v-ATPase, in a nucleotide-bound
state (PDB code 3VR6) (Arai et al., 2013). All the identified
mutations fall into the A subunit of the V1 domain
(Fig. 2A).
Pro12 (Pro27 in human ATP6V1A) resides in the type I
b-turn that is a part of the interaction interface between
subunits A and B. Since the substitution of a proline residue
with an arginine residue affects the main-chain conform-
ation of the b-turn, the mutation may perturb the A–B
interaction (Fig. 2A and B).
Asp85 (Asp100 in human ATP6V1A) makes a hydrogen
bond with Arg89, a guanidium group that makes van der
Waals contacts with adjacent hydrophobic side chains
(Fig. 2B). As a result, the side chain of Asp85 is closely
surrounded by hydrophobic residues, and its replacement
with a bulkier tyrosine residue quite likely causes steric
hindrance and destabilizes the protein folding. This is
supported by the FoldX calculation, which predicted a sig-
nificant increase in free energy (about 13 kcal/mol) upon
the Asp85Tyr mutation.
Asp329 (Asp349 in human ATP6V1A) is located near a
nucleotide-binding site (Fig. 2B) and its side chain is
involved in water-mediated coordination with a magnesium
ion, which plays a critical role in the ATPase activity
(Fig. 2B). Thus, the Asp329Asn mutation possibly impairs
the catalytic function.
Asp351 (Asp371 in human ATP6V1A) is located at the
interface among A, B and D subunits (Fig. 2A). The D
subunit rotates within the A3B3 core along with the ATP
hydrolysis, and thus the rotation process may be affected
by the Asp351Gly mutation. The mutation sites were also
mapped on the cryo-EM structure of the human homo-
logue v-ATPase from the eukaryotic S. cerevisiae (rota-
tional state 1, PDB code 3J9T) (Zhao et al., 2015). As
shown in Fig. 2B, the mapped mutation sites in the S.
cerevisiae structure overlap with those of the E. hirae, sug-
gesting that the predicted impact of the mutations on the
prokaryotic structure is also valid for the eukaryotic
orthologues.
Finally, we generated a homology model of human
ATP6V1A (Supplementary Fig. 1) using S. cerevisiae A sub-
unit as template, obtaining a high-confidence result (C-
score 88% and TM-score 87%). The resulting structure
shows a fold similar to the template (cf. Supplementary
Fig. 1 and 2B), and the mutation sites are in the same
locations of the E. hirae and S. cerevisiae structures.
Effects of ATP6V1A mutations on
protein expression and stability
We addressed the impact of p.Asp349Asn and
p.Asp100Tyr mutations on the ATP6V1A expression and
stability by analysing HEK cells overexpressing ATP6V1A.
Cells were transfected with vectors driving the expression
of the wild-type or mutant variants in association with a
Cherry fluorescent tag for identification. Immunocytochem-
istry of transfected cells coupled with quantitative western
blot analysis showed a decreased expression of both
ATP6V1A mutants that reached significance only for the
Figure 1 Multiple sequence alignment and sequences logo. Multiple sequence alignment between human ATP6V1A and orthologous
sequences. Residues were coloured according to their physico-chemical properties (Zappo colour scheme). Residues affected by the missense
substitutions are indicated by black arrows.
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p.Asp100Tyr variant, and no overt subcellular mislocaliza-
tion of both p.Asp100Tyr and p.Asp349Asn mutants with
respect to wild-type ATP6V1A (Fig. 3A and B). The expres-
sion of the molecular partner, ATP6V1B2, was not modi-
fied either by p.Asp100Tyr or p.Asp349Asn mutation
(Fig. 3B). To investigate the stability of ATP6V1A protein,
we performed a degradation assay by treating transfected
HEK cells with the protein synthesis inhibitor cyclohexi-
mide for various times. Compared to the wild-type isoform,
both mutant ATP6V1A isoforms were less stable, although
degradation was significantly increased only for the
p.Asp100Tyr variant (Fig. 3C).
We next asked whether these findings could also be
observed in patients’ cells. To this end, we analysed the
expression of endogenous ATP6V1A protein in patients’
lymphoblasts and compared it with the respective healthy
parents’ cells (Fig. 3D and E). While the expression of
ATP6V1A and ATP6V1B2 was not modified in
Asp349Asn proband’s cells with respect to his healthy
mother’s cells, a significant decrease of ATP6V1A, but
not ATP6V1B2, expression was observed in Asp100Tyr
proband’s cells. These data are in full agreement with the
structural analysis prediction of a folding defect in the
p.Asp100Tyr mutant (Fig. 2A) that may enhance its
degradation.
ATP6V1A mutations result in
lysosomal abnormalities
To examine the impact of the p.Asp349Asn and
p.Asp100Tyr mutations in the regulation of pH homeosta-
sis, we used the LysoTracker probe to qualitatively evalu-
ate intracellular acidic organelles in HEK cells
overexpressing either pathogenic or wild-type ATP6V1A
variants. Interestingly, the p.Asp349Asn mutant increased,
while the p.Asp100Tyr mutant decreased, LysoTracker
fluorescence intensity (Fig. 4A). The LysoTracker signal
monitors both the actual pH of acidic organelles, namely
endosomal and lysosomal compartments, and their relative
abundance within the cell. Thus, we analysed in parallel the
expression of the endosomal and lysosomal markers, EEA1
and LAMP1, respectively. Whereas EEA1 expression was
unaltered in HEK cells expressing wild-type ATP6V1A or
either pathogenic variants, the p.Asp100Tyr mutant was
associated with a significant decrease of LAMP1 expression
Table 1 Summary of clinical features in four patients carrying ATP6V1A mutations
Patient
1 2 3 4
Origin/sex Caucasian/F Asian/M Caucasian/F Latino/M
Age at follow-up 14 years 8 years 8 years 11 years








Clinical diagnosis Infantile onset epileptic
encephalopathy
ID/epilepsy ID/epilepsy Infantile onset epileptic
encephalopathy
Head circumference At birth: 32 cm = 3rd %ile
(1.9 SD); at 12 years:
44.5 cm4 1st %ile (7
SD): microcephaly
At birth: 33 cm = 10th %ile
(1.2 SD)
Unknown At 12 months:
43.5 cm = 1st %ile (2.2
SD); at 11 years:








2 years 6 months, develop-
mental delay, seizures
7 months, hypotonia, de-
velopmental delay
Epilepsy + + + +
Age at seizure onset 11 months 2 years 10 months 2 years 6 months 11 months
Seizures types Convulsive seizures during
fever at onset, then infantile
spasms, tonic, focal clonic,
focal occipital
Convulsive seizures during
fever at onset, then focal
occipital
Convulsive seizures during
fever at onset, then gener-
alized tonic-clonic
Convulsive seizures during
fever at onset, then
spasms, tonic, clonic and
myoclonic












Brain MRI Hypomyelination, mild brain
and cerebellar atrophy
Normal at 7 years Normal at 7 years Mild atrophy at 1 years









Moderate ID (FSDQ: 53),
poor language, headache,
amelogenesis imperfecta
diagnosed at 3 years, optic
atrophy
Moderate ID, poor language,
mild dysmorphic features
(wide forehead, deep set
eyes, beaked nose), behav-
ioural abnormalities with
autistic traits, wide based
gait, hypotonia
Profound delay, non-verbal,
no visual fixation, colo-
boma of the iris, hypo-
tonic/dyskinetic quadri-
paresis, non-ambulatory
F = female; FSDQ = full scale developmental quotient; ID = intellectual disability; M = male; N/A = not available.
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evaluated by both single cell immunocytochemistry
(Fig. 4B) and western blotting (Supplementary Fig. 2A).
The data suggest that the p.Asp349Asn mutant exacerbates
the acidic pH of intracellular organelles, while the
p.Asp100Tyr mutant leads to a decreased expression of
LAMP1-positive lysosomal structures. Lysosomes fuse
with phagosomal and autophagosomal structures to gener-
ate autolysosomes and v-ATPase also acidifies autolysoso-
mal organelles. We therefore investigated whether
pathogenic ATP6V1A variants affect v-ATPase transloca-
tion to LC3-positive phagosomal structures. To this aim,
we measured the co-localization between the v-ATPase sub-
unit ATP6V1B2 and LC3 in HEK cells expressing wild-type
ATP6V1A or either pathogenic variant. Both p.Asp100Tyr
and p.Asp349Asn resulted in a decreased co-localization
coefficient with respect to wild-type ATP6V1A (Fig. 4C).
However, the v-ATPase translocation induced by cell star-
vation was slightly impaired by p.Asp100Tyr and substan-
tially unaffected by p.Asp349Asn (Fig. 4C). No significant
changes in LC3II/LC3I ratio and p62 accumulation were
observed in both experimental groups (Supplementary
Fig. 2B). These data suggest a significant impact of both
mutations on the recruitment of the v-ATPase to LC3-posi-
tive autolysosomal structures, with slightly impaired autop-
hagic flux only for Asp100Tyr.
To verify whether altered lysosomal pH and levels of
lysosomal markers were also present in patients, we sub-
jected patients’ lymphoblasts to the same analysis.
Experiments using the ratiometric pH probe LysoSensorTM
Yellow/Blue dextran, revealed a significant reduction in
endocytic organelle pH in the Asp349Asn patient’s lympho-
blasts when compared to his healthy mother’s lymphoblasts,
in the absence of any change in the expression of LAMP1
and EEA1 (Fig. 5). Conversely, while the pH of endocytic
organelles was not modified in the Asp100Tyr patient’s
lymphoblasts, a significant reduction in LAMP1 expression
was observed (Fig. 5). Taken together, these data suggest
a gain-of-function effect for the p.Asp349Asn mutation,
characterized by an increased proton pumping into intra-
cellular organelles, and a loss-of-function effect for the
Figure 2 Structural mapping of the missense mutations in the V-ATPase. (A) Left: Crystal structure of the V1 domain from E. hirae
v-ATPase in a nucleotide-bound state (PDB code 3VR6), viewed from the extracellular side (top) and the membrane plane (bottom), shown as the
sphere representation. The A, B, D and F subunits are coloured in cyan, green, violet and brown, respectively, and residues at the mutation sites
are coloured in red. The non-hydrolyzable ATP analogue ANP (phosphoaminophosphonic acid-adenylate ester) is depicted as orange sticks. Right:
Magnified views of the mutation sites presented in the ribbon model. Pro12 and Asp85 are depicted as red sticks, and Arg89, which makes a salt
bridge with Asp85, is shown as sticks with translucent spheres. Some side chains of hydrophobic residues around Arg89 are shown as translucent
spheres, and magnesium ion and its coordinated water molecules are depicted as a purple sphere and small grey dots, respectively. Black dotted
lines indicate hydrogen bonds. Amino acid numbers in parentheses correspond to those of human ATP6V1A. (B) Crystal structures of the A
subunit from E. hirae (orange) and the cryo-EM structure of the A subunit from S. cerevisiae (cyan, PDB code 3J9T) V-ATPase. Mutation sites are
shown as spheres and coloured in red for S. cerevisiae and blue for E. hirae.
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Figure 3 Impact of ATP6V1A mutations on protein expression and stability. (A) Representative images of HEK cells transfected with
vectors coding wild-type ATP6V1A (w.t.), Asp349Asn ATP6V1A (Asp349Asn) or Asp100Tyr ATP6V1A (Asp100Tyr) variants. ATP6V1A immu-
nolabelling, DAPI nuclear stain and Cherry reporter fluorescence are shown. Scale bar = 10 mm. (B) Representative western blot (left) from HEK
cells transfected as above and lysed 24 h after transfection. ATP6V1A and ATP6V1B2 intensities were quantified by densitometric analysis with
respect to GAPDH intensity (right). Data are means  standard error of the mean (SEM) from five independent experiments. *P5 0.05 versus
wild-type; Kruskall-Wallis/Dunn’s tests. (C) Left: Representative western blots of HEK cell lysates stained with anti-ATP6V1A antibody and anti-
GADPH as loading control. Cells were transfected with wild-type, Asp349Asn or Asp100Tyr ATP6V1A variants and incubated with cycloheximide
for 2, 4, 8, 24 h or vehicle (DMSO; 24 h) as a control (–). Right: Densitometric analysis of ATP6V1A intensity with respect to GADPH expressed in
percent of control samples without cycloheximide. Data are means  SEM from four independent experiments. The areas under the respective
curves were compared using the Kruskal-Wallis/Dunn’s tests. *P5 0.05 versus wild-type. (D) Representative western blot from lymphoblast
lysates (30mg) of patient affected by the Asp349Asn mutation (proband) and the healthy mother. (E) Representative western blot from
lymphoblast lysates (30mg) of patient affected by the Asp100Tyr mutation (proband) and the healthy mother. In D and E, ATP6V1A and
ATP6V1B2 intensity were quantified by densitometric analysis with respect to GADPH. Data are means  SEM from four independent experi-
ments. *P5 0.05; Mann Whitney U-test.
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Figure 4 Effects of ATP6V1A mutations on endo-lysosomal markers and v-ATPase recruitment to autophagosomes.
(A) Left: Representative images of HEK cells transfected with wild-type ATP6V1A (w.t.), Asp349Asn ATP6V1A (Asp349Asn) or Asp100Tyr
ATP6V1A (Asp100Tyr) variants and incubated with LysoTracker (200 nM, 1 h). Right: LysoTracker fluorescence intensity was quantified in 38
(wild-type), 41 (Asp349Asn) and 45 (Asp100Tyr) cells from three independent experiments. Individual data and means  SEM are shown.
*P5 0.05, ****P5 0.0001 versus wild-type; Kruskall-Wallis/Dunn’s tests. (B) Representative images and densitometric quantification from HEK
cells transfected as above and immunolabelled with LAMP1 (left) or EEA1 (right). Histograms show quantification of signal intensity. Data are
means  SEM of 24–33 cells per experimental condition, from three independent experiments. **P5 0.001 versus wild-type Kruskall-Wallis/
Dunn’s tests. (C) Representative images from HEK cells transfected as above and immunolabelled with ATP6V1B2 and LC3B under control
conditions or after starvation for 2 h. Graph shows the quantification of ATP6V1B2 and LC3B co-localization using ImageJ software to determine
the Pearson’s correlation coefficient. Data are means  SEM of 30 cells per experimental condition. *P5 0.05 versus respective control;
#P5 0.001 versus non-starved wild-type; §P5 0.001 versus starved wild-type. Data were analysed by two-way ANOVA/Bonferroni’s tests.
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p.Asp100Tyr mutation associated with defects in lysosomal
compartments.
ATP6V1A mutations impact on
neuronal pH homeostasis and
neuronal development
In view of the neurodevelopmental phenotype observed in
the four patients carrying de novo heterozygous ATP6V1A
mutations, we investigated whether the effects on lysosomal
homeostasis observed in HEK cells and patient-derived
lymphoblasts were recapitulated in neurons. To address
this question, we transiently expressed ATP6V1A and the
pathogenic mutants thereof in rat hippocampal neuronal
cultures and evaluated intracellular acidic organelles by
LysoTracker staining at the neuronal soma. As shown in
Fig. 6A, neurons overexpressing p.Asp349Asn resulted in a
significantly higher LysoTracker staining as compared to
wild-type ATP6V1A-expressing neurons. In contrast,
p.Asp100Tyr ATP6V1A overexpression induced a signifi-
cant loss of LysoTracker staining. Thus, the expression
of the two mutants in neurons precisely phenocopies the
effects observed in cell lines, suggesting that such an alter-
ation in pH and lysosomal homeostasis also occurs in brain
cells.
To investigate cellular correlates of the patients’ neurode-
velopmental delay and explore whether the defects
in LysoTracker signal have an impact on neuronal devel-
opment, we transfected rat hippocampal neurons at 7
DIV and analysed neurite elongation at 10 DIV by Sholl
analysis. The analysis revealed a similar and significant loss
of neurite arborization for both p.Asp349Asn- and
p.Asp100Tyr-expressing neurons, indicating that both
pathogenic variants significantly affect the outgrowth
and branching of neuronal processes during development
(Fig. 6B).
ATP6V1A mutations affect synapse
formation in primary neurons
In developing neurons, neurite elongation is followed by
synapse formation and stabilization. V-ATPase is a funda-
mental protein component of synaptic vesicles, where it
allows neurotransmitter loading and regulates synaptic
Figure 5 Effects of ATP6V1A mutations on intracellular organelle pH and endo-lysosomal markers in patients’ cells.
(A) Quantification of endocytic organelle pH in lymphoblasts from patients (probands) bearing either p.Asp349Asn (red) or p.Asp100Tyr (blue)
mutation and the respective healthy mothers (black). Individual data and means  SEM of five to six independent measurements are shown.
*P5 0.05; Wilcoxon matched pairs signed rank test. (B) Representative western blot from lymphoblast lysates (30mg) as defined above. LAMP1,
EEA1 and GADPH as loading control is shown. (C) LAMP1 and EEA1 immunoreactivities were quantified by densitometric analysis and
normalized to GADPH. Data are means  SEM from four independent experiments. *P5 0.05; Mann-Whitney U-test.
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Figure 6 Effect of ATP6V1A mutations on pH homeostasis, development and synaptic connectivity in primary hippocampal
neurons. (A) Left: Representative images of rat hippocampal neurons transfected with wild-type (w.t.), Asp349Asn (Asp349Asn) and Asp100Tyr
(Asp100Tyr) ATP6V1A variants at 7 DIV and incubated with LysoTracker (50 nM, 30 min) at 10 DIV. Right: LysoTracker fluorescence intensity
was quantified in 31 (wild-type), 28 (Asp349Asn) and 33 (Asp100Tyr) neurons from two independent preparations. Individual data and
means  SEM are shown. *P5 0.05, **P5 0.01 versus wild-type; Kruskall-Wallis/Dunn’s tests. (B) Left: Representative neurite traces of 10 DIV
neurons transfected as in A. Right: Sholl analysis of neurite arborization as a function of distance from the soma. Data are means  SEM of 29–33
neurons for experimental group from three independent preparations. **P5 0.01 versus wild-type; Kruskall-Wallis/Dunn’s tests. (C) Left:
Representative images of hippocampal neurons transfected with wild-type ATP6V1A (w.t.), Asp349Asn ATP6V1A (Asp349Asn) or Asp100Tyr
ATP6V1A (Asp100Tyr) variants (top) at 14 DIV and analysed at 17 DIV. White rectangles indicate proximal dendrites shown at high magnification
(bottom). Synaptic boutons were identified by double immunostaining for VGLUT1 (blue) and Homer1 (green). The co-localization panels (col.
points) highlight the double-positive puncta (black), marked by arrowheads, corresponding to bona fide synapses. The merge panels show positive
puncta along transfected branches. Scale bar = 10 mm. Right: Quantitative analysis of synaptic puncta counted on 30-mm branches starting from the
cell body. Data are means  SEM of 27–28 neurons per experimental condition, from three independent preparations. ****P5 0.0001 versus
wild-type; two-way ANOVA/Bonferroni’s tests.
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transmission (Takamori et al., 2006; Takamori, 2016).
Moreover, acidic lysosomes have been recently described
at excitatory postsynaptic sites (Goo et al., 2017;
Padamsey et al., 2017). Accordingly, the expression of
the v-ATPase V1 subunits, ATP6V1A and ATP6V1B2,
was found to increase with in vitro neuronal maturation
and synaptogenesis along with the expression of pre- and
postsynaptic markers (Supplementary Fig. 3A).
To study the effects of ATP6V1A mutants on synapse
formation, we transfected hippocampal neurons at 14
DIV and analysed synapse density at 17 DIV. Excitatory
synaptic contacts were visualized by double immunostain-
ing with the presynaptic marker VGLUT1 and the postsy-
naptic marker Homer1 to identify mature excitatory
synapses unambiguously. Synapse counting at 30 mm dis-
tance from the cell body revealed a significant loss of exci-
tatory synaptic connections for p.Asp349Asn and
p.Asp100Tyr overexpressing neurons, suggesting that
both pathogenic variants dramatically impair the formation
and maintenance of excitatory synapses (Fig. 6C). Similar
effects on the density of excitatory synaptic contacts were
observed after treatment of hippocampal neurons with
the lysosomal enzyme inhibitor leupeptin (Supplementary
Fig. 3B).
Discussion
The phenotypic features observed in the four patients re-
ported here can be typically described as developmental
encephalopathy with epilepsy and subsumed as ATP6V1A
encephalopathy, although a larger number of observations
is necessary to reveal the whole phenotypic spectrum.
However, gathering a large series may take a long time
because ATP6V1A mutations are very rare, and have not
emerged before in large cohorts with epileptic and develop-
mental encephalopathies (Allen et al., 2013; Appenzeller
et al., 2014; McRae et al., 2017); we could only identify
four cases through whole exome sequencing studies on
1444 probands from three continents. Querying the
denovo-db, we found only two potential de novo variants
in the coding regions of ATP6V1A, thus further highlight-
ing the rarity of de novo variants in this gene. Pathogenicity
of the de novo p.Pro27Arg, p.Asp100Tyr, p.Asp349Asn
and p.Asp371Gly variants could be established based on
their: (i) occurrence in four patients with a developmental
encephalopathy with epilepsy, the genome-wide statistical
significance for missense de novo mutations enrichment;
(ii) absence from publicly available databases; (iii) causing
substitutions at highly evolutionarily conserved amino acid
positions; and (iv) predicted highly damaging consequences
emerging from in silico methods and the high intolerance of
the ATP6V1A gene to variations. Accordingly, structural
modelling allowed to localize the mutated sites in regions
of ATP6V1A responsible for either the proper folding of
the subunit (p.Asp100Tyr), the interaction with the V0 B
subunit (p.Pro27Arg) or the function of the v-ATPase com-
plex (p.Asp349Asn, p.Asp371Gly).
As most causative variations occur with very low allele
frequency within each gene and only account for a small
fraction of epilepsy patients (Myers and Mefford, 2015)
sequencing large cohorts of patients, collected through
large networks and gene-matching tools has higher chances
to find multiple affected individuals carrying de novo mu-
tations in the same gene(s) (Hamdan et al., 2017). This
strategy can overcome the challenge to determine whether
the candidate de novo mutations have a causal relationship
with the disease or are found by chance. A statistical frame-
work specifically developed to address this challenge
(Samocha et al., 2014), and successfully applied to devel-
opmental disorders in previous studies (Lelieveld et al.,
2016; McRae et al., 2017), has also proved instrumental
to demonstrate that ATP6V1A reached genome-wide stat-
istical significance for missense de novo mutations enrich-
ment in our cohort.
The Online Mendelian Inheritance in Man (OMIM) cata-
logue contains 59 entries for early infantile epileptic ence-
phalopathies featuring intellectual disability and epilepsy
(https://www.omim.org/entry/308350?search = EIEE&high-
light = eiee) (Supplementary Table 3), caused by mutations
in as many genes, and mentions that similar phenotypes are
also observed in other genetic disorders, highlighting the
extreme genetic heterogeneity underlying this category.
The many genes that have been associated with such
complex developmental epilepsy conditions have revealed
the pathogenic role of mutations affecting diverse molecular
pathways that regulate ion channel functioning, membrane
excitability, synaptic plasticity, neurotransmitter release,
postsynaptic receptors, transporters, cell metabolism, and
many formative steps in early brain development such as
the proliferation and migration of neuronal precursors,
dendritogenesis, synaptogenesis, cell and glial biology
(Guerrini and Noebels, 2014). Our experimental work on
the p.Asp100Tyr and p.Asp349Asn missense substitutions
indicates that ATP6V1A mutations cause functional defects
in v-ATPase physiology with alterations of lysosomal
homeostasis associated with abnormal neuritogenesis and
synaptic density.
The main function of v-ATPase is proton transport and
acidification of intracellular organelles, in particular lyso-
somes that have critical requirements for pH. The func-
tional experiments performed on the p.Asp100Tyr
mutation, causing the more severe phenotype, demon-
strated an increased degradation with impaired expression
of ATP6V1A and lower lysosomal abundance. This finding
was also associated with decreased recruitment of v-ATPase
by autophagosomes under basal and starvation conditions,
suggesting a potential impairment of the autophagic flux, as
recently described in patients with mutations in the acces-
sory v-ATPase subunit ATP6AP2 (Rujano et al., 2017).
Conversely, p.Asp349Asn, which was associated with a
milder phenotype, resulted in decreased endo-lysosomal
pH, with no effects on either expression of the mutant
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protein or lysosomal abundance, pointing to a gain-of-func-
tion effect. This variant slightly impairs v-ATPase trans-
location to autophagosomes under basal, but not
starvation, conditions, suggesting that the formation of
autolysosomes is preserved. These functional findings
were supported by structural modelling results, predicting
that the p.Asp100Tyr mutation decreases protein stability,
whereas p.Asp349Asn affects the catalytic activity of v-
ATPase.
When modelled in hippocampal neurons, these patho-
genic mutations produced the same significant and
divergent effects on lysosomal marker intensity and endo-
lysosomal pH that were observed in cell lines and pro-
bands’ lymphoblasts, reflecting their relevance for the
CNS. Moreover, in primary neurons, both p.Asp100Tyr
and p.Asp349Asn mutants induced significant and compar-
able defects in dendrite development and excitatory synapse
formation. The neuronal phenotype of both mutants dem-
onstrates a previously unexplored role of the v-ATPase in
the processes of neuronal development and connectivity.
Similarities in changes on synapse formation induced by
the two tested mutations and by leupeptin, a known inhibi-
tor of lysosomal function, suggest an important patho-
physiological role of altered lysosomal homeostasis. This
hypothesis is also supported by recent reports on novel
roles of lysosomes at the synapse for the turnover of syn-
aptic proteins, as well as for the plasticity of dendritic
spines (Goo et al., 2017; Padamsey et al., 2017; Sambri
et al., 2017).
Although the precise molecular mechanisms through
which the described de novo mutations result in a develop-
mental encephalopathy with epilepsy remain to be clarified,
we here propose that alteration in lysosomal homeostasis
may represent a novel pathogenic mechanism for this aetio-
logically heterogeneous group of disorders. Further work is
needed to clarify the role of v-ATPase in brain development
and to precisely establish the cellular signalling pathways
that can be altered by loss of lysosomal homeostasis.
It is often impossible to disentangle whether the develop-
mental or epileptic component is more important in con-
tributing to a patient’s presentation. In the four patients
described here, however, there was good correspondence
between severity of epilepsy and overall neurodevelopmen-
tal impairment, which might suggest either a more severe
brain dysfunction leading to both severe impairment and to
the epileptic encephalopathy or a deleterious effect of early
severe and long-lasting epilepsy on development.
Next generation sequencing studies have demonstrated
that sporadic developmental disorders associated with epi-
lepsy, once considered potentially recessive in nature, often
arise from de novo mutations of dominant genes and that
the same gene can be associated with a broader phenotypic
spectrum than originally believed (Mei et al., 2017). Our
findings clearly link the ATP6V1A gene with a dominant
form of encephalopathy after two biallelic homozygous
missense mutations of the same gene had been related in
three individuals to cutis laxa, a rare, severe systemic
disorder, leading to early death in one of the patients and
featuring, in addition to generalized skin wrinkling, marked
hypotonia, dysmorphic facial features, cardiac abnormal-
ities, structural brain abnormalities and seizures (Van
Damme et al., 2017). Although comparison between our
patients and the three previously reported with biallelic
ATP6V1A mutations is only partially feasible, there is evi-
dence that biallelic mutations cause a more complex pheno-
type in which severe neurological manifestations are part of
a multi-organ involvement. A number of additional genetic
developmental disorders with epilepsy, including those
related to PRRT2 (Ebrahimi-Fakhari et al., 2015),
TBC1D24 (Balestrini et al., 2016), RELN (Dazzo et al.,
2015) and SLC2A1 (Wang et al., 2000) genes, have been
associated with both autosomal dominant and more severe
recessive phenotypes.
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